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The proper use of high performance affinity chromatography (HPAC) in the study
of biologically-related systems requires that careful attention be paid to the nature in
which the affinity ligand is incorporated into the stationary phase. Ideally, the behavior
of the immobilized ligand should mimic the behavior of the ligand in its natural
environment.

Retaining the soluble form of the ligand, by avoiding covalent

immobilization completely, is one effective way to retain the activity of the ligand.
Previously, noncovalent immobilization techniques that do not modify the ligand of
interest have included physical entrapment onto low performance supports.
This dissertation introduces an alternative method of entrapment onto supports
that can withstand the high pressures and flow rates associated with HPAC.

The

entrapment method is based on the physical containment of a ligand in a polysaccharidecapped dihydrazide support. This method was optimized for maximum ligand content,
and employed for the immobilization of several different ligands onto HPAC supports, all
of which retained essentially 100% of their binding activity. These supports were used to

study the binding affinities of a variety of drugs and the results were compared with
previously established values obtained from studies using covalently immobilized
ligands.
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CHAPTER 1:
GENERAL INTRODUCTION

Affinity Chromatography
Affinity chromatography is a type of liquid chromatography that employs
biologically related interactions for the separation and analysis of specific analytes within
a sample.1,2

This process is accomplished through the use of a stationary phase

containing a biologically-related agent, known as the “affinity ligand”.1,3 The specific,
reversible interactions between this ligand and its target provide the basis for selective
separations. In this method, one of the pair of interacting molecules is immobilized onto
the support composing the stationary phase, while the other molecule is contained within
the mobile phase or injected sample. Initially, affinity chromatography separations were
conducted using low-performance carbohydrate-based supports, such as agarose,
sepharose or polyacrylamide.

Although easy and inexpensive to use, these support

materials are only structurally stable at low pressures.1-3
High-performance affinity chromatography (HPAC) is an adaptation of affinity
chromatography, combining the selective nature of affinity chromatography with the
small, rigid support particles of HPLC systems, that are capable of withstanding high
pressures. This increased pressure stability provides an efficient and rapid means of
selective separation and analysis of complex biological systems. When compared to its
low-performance counterpart, HPAC tends to be more costly to perform, but the resultant
advantages of this method outweigh these drawbacks.3-5
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One of the central uses of HPAC, which will be discussed in this dissertation, is
its ability to quantitatively characterize biological interactions.

There are many

advantages to using HPAC for these types of studies, the main advantage being the
stability of the immobilized ligand. Because the ligand is incorporated directly into the
stationary phase, the resulting column can often be used for a large number of
experiments. This feature not only reduces the amount of total affinity ligand needed for
the experiments, but also leads to an increase in the overall precision by using the same
stationary phase for multiple studies.3, 6, 7

Zonal Elution.
Zonal elution is the most common HPAC method used to analyze analyte-ligand
binding. This method is preformed by injecting a small plug of analyte onto a column in
the presence of a mobile phase, often a buffer at a physiological pH, that is applied at a
constant flow-rate. The retention time or volume of the analyte is monitored either on- or
off-line using an appropriate detector. Analyte retention is dependent upon the interaction
between the analyte and the immobilized ligand contained in the column and can be
represented by the analyte’s overall retention factor (k) as determined by Equation 1-1.

k

(t R  t M )
tM

or

k

(VR -VM )
VM

(1-1)

In this equation, tR is the retention time of the analyte, VR is the corresponding retention
volume, tM is the void time of the column, and VM is the void volume. A shift in analyte
retention will be caused by a change in binding strength or the number of binding sites
within the column.
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When comparing the retention of an analyte on two separate columns, the
retention factor can be normalized by dividing the calculated retention factor by the total
protein content of the support. The retention factor can be related to the number of
binding sites in the column and to the equilibrium constant or the analyte according to
Equation 1-2.

k

( K a1 n1   K an nn )mL
Vm

(1-2)

Here, Ka1 through Kan are the association equilibrium constants for binding sites 1
through n, n1 through nn represent the number of each type of site in the column, mL is the
moles of total binding sites in the column, and VM is again the column void volume6.

Frontal Analysis.
Frontal analysis, while originally used as a purification technique, has become a
popular tool for obtaining information about the interactions between various ligandanalyte systems. Frontal analysis is preformed when an analyte is continuously applied
to a column containing an immobilized affinity ligand. As the ligand interacts with the
analyte, binding sites on the ligand gradually become saturated. Once all of the available
binding sites on the ligand are bound to the analyte, excess analyte passes through the
column to the detector. This sequence of events creates what is known as a breakthrough
curve. If fast association/dissociation kinetics are present in the system, the breakthrough
curves obtained through frontal analysis measurements can be related to both the
association equilibrium constant (Ka), the moles of active binding sites in the column
(mL) and the concentration of the applied analyte, [A]. Equation 1-3 can be used to
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describe the frontal analysis response for an analyte that binds to an immobilized ligand
at a single site.

1
mLapp



1
1

(mL K a [A]) mL

(1-3)

In this equation, mLapp is the apparent moles of analyte required to saturate the column at
a given concentration of applied analyte. Using Equation 1-3, a plot of 1/mLapp vs. 1/[A]
should yield a linear relationship if there is single-site binding between the ligand and
analyte. The inverse of the intercept will give mL, while dividing the intercept by the
slope of the best-fit line will give Ka.6

Affinity Ligands
Human Serum Albumin (HSA).
HSA is the most abundant protein in human serum, with typical concentrations of
approximately 40-45 g/L. This protein makes up about 60% of the total protein in blood
serum.8, 9 HSA is composed of a single chain of 585 amino acid residues, stabilized by
17 internal disulfide bonds. This globular, heart-shaped protein has a molecular weight
of 66.5 kDa and a size of approximately 80 x 80 x 30 Å.10 HSA has a variety of
functions in the body; however, this dissertation will focus on the role of HSA as a carrier
protein in serum and will investigate the binding of HSA to several target analytes. This
protein has two major binding sites for drugs, Sudlow sites I and II. Sudlow site I, which
is also known as the warfarin-apapropazone site, binds to bulky heterocyclic compounds.
Sudlow site II, the indole-benzodiazapine site, binds to aromatic carboxylic acids.10-12
HSA is commonly used as an immobilized ligand in HPAC to study drug binding. 13 This
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binding can be affected by many factors,14 and portions of this dissertation will
investigate the effects of protein modification due to glycation on drug binding.
In adults, an average of 6-15% of serum HSA is glycated, with that value
increasing to 20-30% in adults with type II diabetes.15, 16 Glycation, or the modification
of a protein through the reaction between a reducing sugar and a free amine group on the
protein, can take place when HSA is in the presence of glucose. This process initially
forms a reversible Schiff base that can rearrange to form an irreversible ketoamine, also
known as an Amadori product.15

This process is especially prevalent in diabetes,

resulting in the increased percentage of glycated HSA. Glycation is thought to alter the
secondary and tertiary structure of HSA, potentially affecting the binding of analytes to
HSA,17 as some of the glycation sites are near Sudlow sites I and II.18 Studies have been
conducted to investigate the effect of glycation on the binding of certain drugs to HSA,
including the use of covalently immobilized HSA in HPAC.19-22 This dissertation will
present data on this effect, as obtained through the use of an entrapment method for
immobilization and HPAC zonal elution binding studies.

α1-Acid Glycoprotein (AGP).
Human AGP, also known as orosomucoid, is a negatively charged, acidic
glycoprotein, consisting of 59% protein and 41% carbohydrate. This 41 – 43 kDa
glycoprotein has a serum concentration of approximately 1 g/L; however, different
conditions affect his concentration, including acute inflammation, cancer, rheumatoid
arthritis, and pregnancy. AGP is among the major binding proteins for drugs in serum. It
is a major transport protein for basic drugs, but it has also been shown to be a carrier for
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steroids and acidic drugs.23, 24 The binding of drugs to AGP has been extensively studied
and reviewed.23-28
AGP contains seven total binding sites: five low affinity sites for the binding of
endogenous substances, and two drug-binding sites (i.e., one with low affinity and one
with high affinity). For practical purposes, one drug binding site (i.e., the high affinity
site) is the only site considered of clinical relevance.23, 24 The binding affinity of drugs to
AGP is also dependent upon the relative concentrations of the three genetic variants of
AGP. These variants can exhibit different drug specificity.23, 24, 29 For the studies in this
dissertation, the same sample of commercial (unfractionated) AGP was used for all drugbinding studies, eliminating binding discrepancies based on variant concentration.
The binding of drugs to AGP has been studied using ultra-filtration and
equilibrium dialysis.23,25, 29 Recently an immobilization technique was developed making
it possible to study AGP-drug interactions via HPAC. This immobilization was achieved
through the mild oxidation of carbohydrate residues on the surface of AGP.26, 28 This
dissertation will investigate the use of the entrapment method as a means for AGP
immobilization in the preparation of HPAC supports. Data obtained from AGP-drug
binding studies, with this approach is presented in Chapter 3 and Chapter 5.

Protein G.
Protein G is a bacterial cell surface protein that is commonly used as a binding
agent in affinity chromatography and other methods for the selective adsorption of
immunoglobulins and antibodies.30-33

This protein is produced by groups C and G

streptococci and binds to the Fc regions of many types of immunoglobulins, including all
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subclasses of mouse immunoglobulin G (IgG), rabbit IgG, goat IgG, and human IgG31.
Protein G has strong binding to these targets at a neutral or slightly acidic pH (e.g., pH 57.5) and yet can be made to release any retained immunoglobulins at pH 2.5-3.0.31 These
properties have made protein G popular as a binding agent for the purification of
immunoglobulins and as a secondary binding agent that can be used to adsorb antibodies
for use in immunoaffinity chromatography or immunoassays.30-33
Over the last decade there have been several examples in which immobilized
protein G has been used in small affinity columns or in affinity capture systems for the
adsorption of immunoglobulins.34-37

The small size of many of these columns and

affinity sorbents ideally requires that a relatively large amount of protein G be present in
a small volume for the effective capture of the desired target.37 However, no previous
studies have determined the maximum amount of protein G that can be placed on
common porous HPAC supports. An estimate of the maximum amount of protein G that
can be covalently immobilized to silica with various pore sizes and an examination of the
binding of these supports to immunoglobulins, using rabbit IgG as a model, is presented
in Chapter 6.

Traditional Immobilization Techniques for HPAC
The proper use of HPAC in the study of biologically-related systems requires that
careful attention be paid to the nature in which the affinity ligand is incorporated to the
stationary phase. The type of immobilization method is extremely important because it
can alter the actual or apparent activity of the ligand within the support.3, 13, 38 In order to
obtain accurate protein binding data, consideration of the type of ligand immobilization
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technique is essential. Ideally, the behavior of the immobilized ligand should mimic the
behavior of the ligand in its natural environment.

In this dissertation, the term

“immobilization” will not be limited to a covalent linkage of the ligand to the support;
rather it will be used to refer to the way the ligand is incorporated within the support.
Traditionally, a ligand, such as a protein, is covalently immobilized onto the
surface of the HPAC support. This immobilization can be instituted through several
different functional groups on the ligand. During protein immobilization, free amine
groups are often used in techniques such as the cyanogen bromide method, reductive
amination (i.e. the Schiff base method), the N-hydroxysuccinimide technique, and the
carbonyldiimidazole method.39-44 Protein immobilization is not limited to free amine
groups alone; other functional groups that may be employed include sulfhydryl groups,
carboxyl groups, and carbonyl groups.28, 45
Complications can arise during covalent immobilization because there is often
more than one functional group present on a ligand such as a protein. This can not only
lead to attachment of the ligand to the support through multiple sites but can also lead to
an orientation of the ligand that interferes with the ligand’s binding sites, as shown in
Figure 1-1. These effects can lead to a decrease or complete loss in the activity of the
ligand.2,28,38,46,47

However, multi-site attachment and random orientation can be

minimized by coupling the ligand to the support through functional groups that occur in a
select number of places in the structure of the ligand. One example is the use of
carbohydrate chains in glycoproteins like AGP for site-selective attachment to hydrazideactivated supports.28
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Figure 1-1.

Covalent immobilization techniques can result in several orientations of
the immobilized ligand: (a) proper orientation; all binding sites are
unobstructed and available for analyte binding, (b) multisite attachment;
the ligand is immobilized through multiple sites, (c) improper orientation;
the ligand is immobilized through residues at or near the binding sites.
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Binding sites
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Noncovalent immobilization techniques can involve the simple adsorption of a
ligand to a surface, the binding of one ligand to a secondary ligand, or the formation of a
coordination complex between the ligand the support.

An alternative noncovalent

immobilization method is that of entrapment or encapsulation. Physical entrapment of a
ligand within a support is a technique that has been widely employed in the field of
chromatography for many years. The long-standing definition of entrapment focuses on
the physical containment of a ligand within a support that contains small pores or a
highly cross-linked polymer network.48-50 The attraction to this type of method stems
from the lack of modification to the ligand itself; therefore any conformational changes to
the ligand are avoided, and all of the ligand’s activity is retained.
Physical containment of a ligand has been popularized through the wide usage of
sol-gel materials. Most recently, bioencapsulation of ligands in sol-gels, including but
not limited to proteins, enzymes, phospholipids, and nucleic acids, has been used for the
development of biosensors and bioreactors. Developments in whole cell encapsulation
has lead to advancements in cell-based biosensing and bioproduction, allowing the
development of artificial organs.48-52

Liposomal entrapment has been used for the

encapsulation of a wide variety of ligands, including anti-infective agents, vaccine
adjuvants, peptides and DNA.53,54

These previous examples all employ physical

containment of the ligand of interest, allowing for increased ligand lifetime and
prolonged ligand activity through degradation prevention. Traditionally, entrapment has
been limited to low-performance supports and is therefore restricted to low pressures and
flow rates.48-57
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Entrapment for Ligand Immobilization in HPAC
This dissertation introduces an alternative approach to entrapment that is capable
of withstanding conditions used in HPAC. This entrapment method is based on the
physical containment of a ligand in a polysaccharide-capped dihydrazide support. This
support is produced by first activating a porous or nonporous silica with hydrazide
groups.58 This hydrazide-activated support is then incubated with a solution containing
the ligand of interest and an oxidized form of a large polysaccharide. The oxidized
polysaccharide will be prepared according to methods adopted from previous work in the
oxidation of glycoproteins by periodate.28, 59, 60
When these oxidized polysaccharides are incubated with the hydrazide-activated
support, aldehyde groups on the oxidized polysaccharide should form a stable covalent
bond with the hydrazide groups. This process should entrap a portion of the ligand in the
support. The initial examination and optimization of the entrapment method is presented
in Chapter 2.

Overall Goal and Summary of Work
The overall goal of this dissertation is to examine the use of entrapment and other
methods as ligand immobilization techniques for HPAC. Chapter 2 will first examine
the viability of the entrapment method as an alternative to the traditional covalent
immobilization of ligands for use with HPAC. The rest of Chapter 2 will focus on the
optimization of the entrapment method in an effort to maximize the protein content of
immobilized ligands on such supports.

Chapter 3 will examine the optimized

entrapment parameters through the zonal elution analysis of drugs with known binding to
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HSA. These results will be compared with data obtained from a support made with the
Schiff base method under identical conditions. Chapter 4 will assess the ability of the
entrapment method to immobilize glycated HSA, through zonal elution studies of sitespecific probe compounds and a series of sulfonylureas. The resulting data for the
entrapped glycated HSA will be compared not only to the values obtained for the
entrapped HSA but also to established literature values. Chapter 5 will test the ability of
the method to entrap AGP and examine the binding of a series of drugs to entrapped HSA
and entrapped AGP. Association equilibrium values will be calculated based on the
measured retention factors and column efficiency will be compared based on plate height
calculations. Chapter 6 will describe work done to create high-capacity protein G
supports through traditional covalent immobilization techniques. Finally, Chapter 7 will
discuss the future prospects of the entrapment method, including plans for further
optimization and application to a wider variety of chromatographic situations.
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CHAPTER 2:
ENTRAPMENT – AN ALTERNATIVE IMMOBILIZATION METHOD FOR USE
IN HPAC BINDING STUDIES: METHOD DEVELOPMENT AND
OPTIMIZATION

Introduction
Affinity chromatography employs the interactions between a ligand and a
particular analyte to determine the manner in which ligand-analyte binding occurs.
Traditionally, the ligand is covalently immobilized onto the surface of the support. This
immobilization can be instituted through several different functional groups on the
ligand. Free amine groups on protein-based ligands are often used in immobilization
techniques such as the cyanogen bromide method, reductive aminiation (i.e., Schiff base
method), the N-hydroxysuccinimide technique, and the carbonyldiimidazole method.1-6
However, protein immobilization is not limited to free amine groups alone; other
functional groups that may be employed include sulfhydryl groups, carboxyl groups, and
carbonyl groups.7,8
Complications can arise during covalent immobilization because there is often
more than one functional group present on a ligand such as a protein. This can not only
lead to multi-site attachment but can also lead to random orientation which can lead to a
decrease or complete loss in the activity of the ligand.7, 9-11 Noncovalent immobilization
techniques can involve the simple adsorption of a ligand to a surface, the binding of one
ligand to a secondary ligand, or physical entrapment or encapsulation.12

These

techniques avoid undesirable immobilization effects because the ligand itself is not
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modified, therefore retaining all ligand activity.13 Traditionally, entrapment has been
limited to low-performance supports and has therefore been restricted by pressure and
flow rate constraints.14
The work in this chapter introduces an alternative approach to entrapment that is
capable of withstanding conditions used in high performance ligand chromatography
(HPAC). This entrapment method involves the physical containment of a ligand in a
polysaccharide-capped dihydrazide support. This method is performed by first activating
a porous or nonporous silica support with hydrazide groups, as prepared according to a
previously-published technique.15 This hydrazide-activated support is then incubated
under slightly acidic pH conditions with a solution containing the ligand of interest and
an oxidized form of a large polysaccharide. The oxidized polysaccharide is prepared
according to methods adopted from previous work in the oxidation of glycoproteins by
periodate.7
When these oxidized polysaccharides are incubated with the hydrazide-activated
support, aldehyde groups on the oxidized polysaccharide should form a stable covalent
bond with the hydrazide groups, a reaction known to occur even in a neutral aqueous
buffer15, 16. This process should entrap the ligand in the support, as shown in Figure 2-1.
The performance of this method will be examined and optimized through the use of
human serum albumin (HSA) as a model ligand. The binding capacity and affinity of
HSA will be determined and compared with data obtained from covalently immobilized
HSA supports.
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Figure 2-1. General scheme for entrapment of a biomolecule such as a protein using a
glycogen-capped and hydrazide-activated support.

Hydrazide-activated silica

Protein

Oxidized Glycogen

Entrapment Support

Protein
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Frontal Analysis.
The method of frontal analysis was used to determine the association equilibrium
constants (Ka) and the moles of active binding sites (mL) for S-warfarin and L-tryptophan
(see structures in Figure 2-2). If fast association/dissociation kinetics are present in a
drug-protein system, the breakthrough curves obtained through frontal analysis
measurements can be related to both Ka, mL and the concentration of the applied analyte,
[A]. The Equation 2-1 can be used to describe the frontal analysis response for an
analyte that binds to an immobilized protein through a single site.17

1
mLapp



1
1

(mLapp K a [A]) mL

(2-1)

In this equation, mLapp is the apparent moles of analyte required to saturate the column at
a given concentration of applied analyte. Using Equation 2-1, a plot of 1/mLapp vs. 1/[A]
should yield a linear relationship is there is single-site binding between the ligand and
analyte. The inverse of the intercept will give mL, while dividing the intercept by the
slope of the best-fit line will give Ka.17

Experimental
Reagents.
The p-periodic acid (periodic acid reagent, or H5IO6), glycogen (from bovine
liver), HSA (Cohn fraction V, 99% globulin free, 99% fatty acid free), human alpha 1acid glycoprotein (AGP, 99%), glycated HSA (95% lyophilized, lot no. 115K6108), goat
immunoglobulin G (IgG), S-warfarin, L-tryptophan, insulin, myoglobin, streptavidin,
avidin, ferritin, monobasic and dibasic potassium phosphate salts, sodium chloride and
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Figure 2-2.

Structures of S-warfarin and L-tryptophan.
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sodium acetate were purchased from Sigma-Aldrich (St. Louis, MO). The Nucleosil Si50, Si-100, Si-300, Si-500 and Si-1000 silica (all 7 m diameter, with nominal pore sizes
of 50 Å, 100 Å, 300 Å, 500 Å, and 1000 Å, respectively) were purchased from
Macherey-Nagel (Düren, Germany). The nonporous glass beads (3-10 m particle size)
were purchased from Polysciences (Warrington, PA).

Reagents for the micro

bicinchoninic acid (BCA) protein assay were purchased from Pierce (Rockford, IL).
Other chemicals were of the purest grades available. The Econo-Pac 10 DG disposable
30 x 10 mL desalting columns were purchased from Bio-Rad Laboratories (Hercules,
CA). All solutions were prepared using water from a NANOpure purification system
(Barnstead, Dubuque, IA) and filtered with a 0.20 µm GNWP nylon membrane from
Millipore (Billerica, MA).
Apparatus.
The chromatographic system consisted of two Jasco PU-980i intelligent HPLC
isocratic pumps (Tokyo, Japan), a Rheodyne Advantage PF ten-port valve (Cotati, CA),
and a Jasco UV-975 UV/Vis detector.

Data were collected using an interface and

software from National Instruments (Austin, TX). The temperature of the columns and
mobile phases was controlled using a PolyScience circulating VWR circulating water
bath (Buffalo Grove, IL) and a water jacket from Alltech. All columns were packed
using an HPLC column slurry packer from Alltech.
Methods.
Preparation of Oxidized Glycogen.
The procedure for oxidizing glycogen was adapted from previously-published
work and optimized for use with the entrapment method.7,

18, 19

The oxidation of
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glycogen was done in a pH 5.0 buffer containing 20 mM sodium acetate and 15 mM
sodium chloride. A 10.0 mL solution was prepared by dissolving 200 mg of periodic
acid and 50 mg of glycogen from bovine liver in the aforementioned buffer. This
solution was covered in aluminum foil – due to the light sensitivity of periodic acid and
allowed to shake at room temperature for 12-24 h. After oxidization, the glycogen was
purified using three Econo-Pac 10DG disposable desalting columns and pH 5.0, 0.10 M
potassium phosphate buffer. This process was done by first removing the upper cap of
each column and decanting the excess storage buffer.

The next step was a buffer

exchange via the addition of 10.0 mL of pH 5.0, 0.10 M potassium phosphate buffer to
each column. Next, 3.3 mL of the oxidized glycogen sample were allowed to pass
through each column causing the elution of the newly introduced potassium phosphate
buffer. To each column, 4.0 mL of potassium phosphate buffer was then added to elute
the oxidized glycogen. The larger glycogen molecules eluted from the column during
this step, while the smaller periodic acid molecules took much longer to pass through the
column matrix. The three fractions of purified oxidized glycogen were collected and
combined to produce a 4.2 mg/mL solution with a final volume of 12.0 mL. This
solution was stored at 4 °C.
Preparation of Entrapped Supports.
Diol silica was prepared from nonporous glass beads and Nucleosil Si-50, Si-100,
Si-300, Si-500 or Si-1000, and was then converted into a dihydrazide-activated form
according to previously-established procedures.15 A 50 mg/mL stock solution of HSA
was prepared with pH 5.0, 0.10 M potassium phosphate buffer. To create the entrapped
support, 30 mg of dihydrazide activated silica was combined with 500 µL of the HSA
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solution. This mixture was sonicated under vacuum for 15 min to ensure the proper
mixing of the silica and protein. A 100 µL portion of the purified oxidized glycogen was
added, and the mixture was shaken at room temperature for 24 h. During the final hour
of the reaction, 200 µL of a 2 mg/mL oxalic dihydrazide solution in the same buffer was
added to the reaction mixture to cover any remaining aldehyde groups on the silica
support. After immobilization, the support was washed several times with pH 7.4, 67
mM potassium phosphate buffer A control support was also prepared through the
addition of a 500 µL aliquot of potassium phosphate buffer in place of the HSA solution.
Binding of an analyte to the prepared control support was used to monitor non-specific
interactions in the frontal analysis studies.
After immobilization, all supports were downward slurry-packed into separate
stainless steel columns at 4000 psi using pH 7.4, 67 mM potassium phosphate buffer as
the packing solution. Columns used in the S-warfarin frontal analysis studies were
packed into 5.0 cm  2.1 mm I.D. stainless steel columns, while those used in the Ltryptophan frontal analysis studies had dimensions of 1.0 cm  2.1 mm I.D. All columns
were stored at 4 °C in the packing solution.
Initial Chromatographic Studies.
All samples for the chromatographic studies were prepared in pH 7.4, 67 mM
potassium phosphate buffer. The warfarin solution was prepared through the dilution of a
30 μM stock solution of S-warfarin. The L-tryptophan solution was prepared through the
dilution of a 100 μM of L-tryptophan. This pH 7.4 buffer was also used as the mobile
phase. All solutions were stored at 4 °C. Prior to use, all mobile phases were filtered
through a 0.20 µm GNWP nylon filter and were degassed for a minimum of 20 min. The
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column temperature was maintained at 37.0 (±0.1) °C during all experiments through the
use of a temperature-controlled water jacket.
Frontal analysis studies were performed using two well-characterized probe
compounds for HSA: S-warfarin, known to bind to Sudlow site I, and L-tryptophan,
known to bind to Sudlow site II.20, 21 In the frontal analysis studies, the column was first
equilibrated with pH 7.4, 67 mM potassium phosphate buffer, with the equilibration
being completed between each successive run. A switch was made between the pH 7.4
buffer and the sample solution using an automated ten-port valve at the initiation of data
collection. The sample solution was continuously applied to the entrapped HSA column
until all binding sites were saturated, producing a breakthrough curve. The valve was
then switched to return the flowing mobile phase to the pH 7.4 buffer, which was used to
elute any remaining bound analyte from the column.

All runs were performed in

triplicate on both the entrapped HSA column and the control column. These studies were
conducted to not only determine the activity of the entrapped HSA but also to determine
an association equilibrium constant for comparison with an established immobilization
method. Both S-warfarin (304 nm) and L-tryptophan (280 nm) were analyzed, with
concentration ranging from 5 to 25 µM and 1 to 25 µM, respectively. Breakthrough
times for each analyte on both the entrapped HSA column and control column were
determined by using the equal area method. The amount of analyte needed to saturate
these columns was determined by integration of the resulting breakthrough curves, after
correcting for the void time of the system and non-specific binding to the support, as
measured on the control column.22

The non-specific binding of S-warfarin and L-
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tryptophan was found to be less than 5% and 9%, respectively, of the total binding
measured on columns containing entrapped HSA.
Protein Content Determination Using the Micro BCA Assay.
A sample of each support was washed several times with water and dried at 50
°C.

These samples were used to determine the overall protein content of support

materials used in entrapped HSA columns. This determination was done through use of a
micro bicinchoninic acid (BCA) protein assay.23,
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This assay was used not only for

analysis of the HPAC supports but also for the smaller samples that were prepared during
all subsequent optimization experiments.
Entrapment Optimization.
After initial chromatographic measurements were made, studies were done to
determine the optimum conditions for the entrapment method in an effort to obtain
maximum protein content.

These studies investigated the effect of porosity, the

concentration of both the glycogen and protein in the initial reaction mixture, the rate of
immobilization, and the ratio of periodic acid to glycogen with regard to the overall final
protein content. All studies were done with small samples of silica and analyzed for
protein content using a micro BCA assay.

Results and Discussion
Initial Studies of the Entrapment Method.
The viability of the entrapment method as a means to create HPAC supports
containing a biologically active ligand was initially tested through the injection of Swarfarin onto three separate HPAC columns. These columns included an entrapped HSA
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support, a control support prepared in the same manner as the entrapped HSA support but
without the addition of HSA to the reaction mixture, and a support containing only
dihydrazide-activated silica. Injections on the entrapped HSA support indicated not only
that HSA was entrapped, but also that it was accessible for binding with small molecules
such as S-warfarin. Injections on the two subsequent supports indicated that S-warfarin
had low nonspecific binding to both the dihydrazide activated silica and the oxidized
glycogen on the control support.18 These studies indicated that the entrapped method
could be a useful technique for the immobilization of a protein for drug-protein binding
studies in HPAC. In the remainder of this chapter, the entrapment method was examined
using frontal affinity chromatography and optimized through variations of individual
initial reaction conditions.
Frontal Analysis Studies of Entrapped HSA.
Initial frontal analysis experiments employed S-warfarin as the model analyte for
the study of drug binding to Sudlow site I. For this study, supports from several pore
sizes of silica were prepared. Silica with pore sizes of 50 Å, 100 Å, 300 Å, 500 Å, or
1000 Å was converted to dihydrazide-activated silica and used for the preparation of both
control supports and supports containing entrapped HSA.15 These supports were slurry
packed into separate 5.0 cm × 2.1 mm I.D. columns. A concentration range of 5-20 µM
S-warfarin was used for this frontal analysis study. Breakthrough times were calculated
from the resultant curves and mLapp values were determined at each analyte concentration.
Breakthrough curves from the frontal analysis of S-warfarin on the 300 Å entrapped HSA
column can be seen in Figure 2-3.
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Double-reciprocal plots of 1/mLapp vs. 1/[S-warfarin] were obtained for each set of
columns. Figure 2-4 shows a double-reciprocal plot made according to Equation 2-1 for
frontal analysis data obtained for the binding of S-warfarin to an entrapped HSA support
with the following pore sizes of 50 Å, 100 Å, and 300 Å. The correlation coefficients
were 0.998 (n = 5) for the 50 Å pore size silica, 0.997 (n = 5) for the 100 Å pore size
silica and 0.994 (n = 5) for the 300 Å pore size silica. No noticeable deviations from
linearity were noted over the concentration range studied for any of these pore sizes.
This indicated that there was single-site binding for S-warfarin to the entrapped HSA
under the conditions of this experiment (pH 7.4 and 37 ºC), agreeing with previous work
using covalently immobilized HSA.25 Similar binding behavior was observed in frontal
analysis experiments performed using entrapped HSA columns prepared with other pore
size silica supports.

The double-reciprocal plots for these studies had correlation

coefficients ranging from 0.994-0.998 (n = 5) over the same concentration range as
shown in Figure 2-4.
By using the intercepts and slopes from these double reciprocal plots along with
Equation 2-1, it was possible to determine the association equilibrium constants for Swarfarin with the entrapped HSA columns. The five pore sizes of silica supports gave an
average association equilibrium constant of 1.7 (± 0.2) × 105 M-1 at pH 7.4 and 37 oC.
These results are in good agreement with values reported for soluble HSA (e.g., 2.0 × 10 5
M-1) as well as those measured for HSA that had been immobilized by the Schiff base
method (e.g., 2.0 × 105 M-1).25
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Figure 2-3.

Breakthrough curves for S-warfarin on the 300 Å pore size entrapped HSA
column. Concentrations from left to right: 25, 20, 15, 10, and 5 µM Swarfarin.
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Figure 2-4.

Double-reciprocal plot made according to Equation 2-1 for frontal
analysis data obtained for the binding of S-warfarin to HSA that had been
entrapped on silica with the following pore sizes: 50 Å (□), 100 Å (■), and
300 Å (▲). The best-fit slopes and intercepts for these plots were as
follows: 50 Å pore size silica, slope = 0.189 (±0.003) x 104, intercept =
2.14 (±0.04) x 107; 100 Å pore size silica, slope = 0.330 (±0.009) x 104,
intercept = 2.0 (±0.1) x 107; 300 Å pore size silica, slope = 0.26 (±0.01) x
104, intercept = 2.1 (±0.1) x 107. The correlation coefficients were 0.998
(n = 5) for the 50 Å pore size silica, 0.997 (n = 5) for the 100 Å pore size
silica and 0.994 (n = 5) for the 300 Å pore size silica. The conditions are
given in the text. The error bars represent a range of  1 S.D.
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A frontal analysis study was also conducted to examine the binding of HSA to Ltryptophan, a compound with known single site binding to Sudlow Site II. For this study,
both control and entrapped HSA supports were prepared from 300 Å pore size silica and
were slurry packed into separate 1 cm × 2.1 mm I.D. columns. A concentration range of
1-25 µM L-tryptophan was used for this frontal analysis study. The double-reciprocal
plot of 1/mLapp vs 1/[L-tryptophan] had a correlation coefficient of 0.991 (n = 7),
indicating agreement with a system that had single site binding.26 Using Equation 2-1 a
value of Ka for L-tryptophan on this support was calculated to be 2.0 (± 0.5) × 104 M-1.
This value was in good agreement with a value of 2.4 (± 0.3) × 104 M-1 that has been
previously reported for HSA immobilized by the Schiff base method. The association
equilibrium values that were determined for both S-warfarin and L-tryptophan are shown
in Table 2-1.
Activity of Entrapped HSA.
One of main advantages of noncovalent immobilization is the ability to avoid
undesirable effects such as multisite attachment and improper orientation that can lead to
the loss of activity for a covalently immobilized protein. The specific activity of a
support can be obtained using Equation 2-1 and the data from the double reciprocal plots
created from the frontal analysis studies. Recall that the term mL in Equation 2-1
represents the total binding capacity of the column, or the moles of ligand available for
binding. These results paralleled those for the amount of entrapped HSA that was
determined by the BCA assay. Using the known HSA content of these supports and the
binding capacities that were measured via frontal analysis, it was possible to determine
the specific activity for the entrapped HSA in each column.
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Table 2-1.

Results obtained from frontal analysis studies of S-warfarin and Ltryptophan on entrapped HSA.

Analyte

Column
Length

Protein Content
(moles)

Specific
Activity

Association
Equilibrium
Constant (M-1)

S-warfarin

5 cm

1.3 (± 0.2) × 10-8

0.91 (± 0.29)

2.0 (± 0.3) × 105

L-tryptophan

1 cm

6.9 (± 0.1) × 10-9

0.88 (± 0.14)

2.0 (± 0.5) × 104

*

* Average values for all pore sizes.
a

The values in parentheses represent a range of ±1 S.D.

38
The average specific activity for the five columns used in the frontal analysis
studies of S-warfarin was 0.92 (± 0.29). This value is significantly higher than the typical
specific activity of 0.67 that has been reported for S-warfarin with HSA that has been
covalently immobilized by the Schiff base method.25

Similar work with sulfhydryl-

reactive immobilization methods for HSA has given specific activities of 0.81-0.87.8 The
specific activity determined for entrapped HSA with L-tryptophan was 0.88 (± 0.14).
This value was also significantly higher than the specific activity of 0.34 that has been
reported for L-tryptophan with HSA which has been covalently immobilized by the
Schiff base method.26 Both of the specific activities determined for entrapped HSA were
statistically equal to 100%, which indicated that Sudlow sites I and II of the entrapped
HSA were completely available for binding. This increased column activity translates
into more efficient supports for use in HPAC drug-protein binding studies.
Preliminary evaluations of the entrapment method revealed that it was a viable
alternative to covalent immobilization. These studies indicated that small molecules were
able to access both Sudlow Sites I and II, and that statistically, the entrapped HSA did not
suffer any loss of activity during the immobilization process.

The association

equilibrium constants obtained using the entrapment method were also in good agreement
with those established for covalent immobilization. The next step was to isolate and
modify specific parameters of the entrapment method in an attempt to optimize the
binding capacity of the entrapped support.
Effect of Pore Size on Protein Entrapment.
The first parameter investigated in the optimization of the entrapment method was
the porosity of the support.

This study looked at nonporous silica in addition to silica
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with pore sizes ranging from 50 Å to 1000 Å. In this work, 10 mg of dihydrazide
activated silica was combined with 125 µL of 8 mg/mL HSA and 500 µL of oxidized
glycogen. The reaction mixture was brought to a total volume of 1 mL with the addition
of 365 µL of pH 5.0, 0.10 M potassium phosphate buffer. This mixture was shaken at 4
o

C for 12 h. After immobilization was complete, the samples were washed several times

with water and dried for several days at 50 °C. The protein content was then determined
using a micro BCA assay. The protein content in all supports was similar, averaging 26.8
(± 3.2) mg HSA per gram silica, as seen in Figure 2-5. Entrapment of the nonporous
support resulted in a protein content of 30.3 (± 0.8).
When taking into account the surface areas of the supports, the total surface area
could be dissected into two regions: the interior of the pore and the outermost surface of
the silica. By comparison, the nonporous support acquires 100% of its surface area from
the outer surface, while the majority of the surface area for the porous supports would be
contributed by the interior of the pores. The results obtained in this study suggested that
the mechanism for protein entrapment under the given preparation conditions involved
HSA being held by the oxidized glycogen within pockets at or near the outer surface of
the supports, where similar surface areas would have been present for each of the
supports examined.

Comparison of the entrapment results with those for covalent

immobilization techniques showed similar results for all pore sizes in terms of the protein
content per unit of surface area of the support.8
Effect of Amount of Glycogen on HSA Entrapment.
The amount of HSA that could be entrapped was examined as a function of the
amount of glycogen that was used during the entrapment process. This was studied by
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Figure 2-5.

Amount of HSA that was entrapped on various types of glycogen-capped
and hydrazide-activated porous silica or nonporous glass beads. The pore
size or type of support was varied while all other entrapment conditions
(e.g., the amount of added protein and oxidized glycogen) were held
constant. The conditions are given in the text. The error bars represent a
range of  1 S.D.
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incubating 10 mg of 300 Å hydrazide-activated silica with various amounts of oxidized
glycogen and a solution containing 8 mg/mL HSA. The amount of glycogen in this study
ranged from 0.84 to 35.70 mg oxidized glycogen per gram of silica in the reaction
mixture. Other than the change in the amount of glycogen in the reaction mixture, all
conditions used in the previous porosity study were kept constant. The protein content
was again determined using a micro BCA assay. The results are summarized in Figure
2-6. In this plot, the ratio of glycogen per silica (in mg/g) represents the relative amount
of glycogen that was added, while the ratio of entrapped HSA per support (also in mg/g)
represents the amount of entrapped HSA that was obtained with the final supports.
It can be seen from Figure 2-6 that as amount of oxidized glycogen increased
from 0.84 mg to 17 mg per gram of silica, the amount of immobilized HSA increased
from 1.2 to 44 mg/g. A further increase in the amount of added glycogen to levels of 21
mg per gram silica gave a relatively consistent amount of entrapped HSA. However, the
use of larger amounts of glycogen (up to 36 mg/g silica) may have given a slight decrease
in the amount of entrapped HSA. The exact reason for this possible small decrease is not
known, but it may be due to the smaller amount of time that was allowed for the
entrapment of HSA to occur as a larger excess of glycogen was available to bind to the
hydrazide-activated support. From this point on, the amount of glycogen in the reaction
mixture was set at an optimized value of 20 mg per gram silica.
Rate of Protein Immobilization.
All studies until this point have illustrated that the entrapment method is a viable
alternative to covalent immobilization techniques for use in HPAC binding studies. The
main covalent immobilization technique for such work is the Schiff base method. The
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Figure 2-6.

Amount of entrapped HSA as a function of the amount of oxidized
glycogen that was used for the entrapment process. The conditions are
given in the text. The error bars represent a range of  1 S.D.
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association equilibrium constants for both S-warfarin and L-tryptophan were in good
agreement between the two methods, and similar protein content was achieved. The
largest variation between the two methods up to this point was the specific activity of the
immobilized protein, with little loss of activity when using the entrapment method as
compared to an approximately 44% loss of activity when using the Schiff base method.
The next step in the optimization of the entrapment method was to determine and
compare the rate at which immobilization occurs.
In this study, 300 Å pore size silica was used as the support and all concentrations
of the reaction components were held constant. The time allowed for entrapment to
occur was varied from 1 to 40 hours. Seven samples were taken over this time period and
a micro BCA assay was used to determine the amount of immobilized protein. The
results of this study can be seen in Figure 2-7.
A maximum amount of entrapped HSA or 37.6 (±0.6) mg HSA/g support was
achieved within the first 8 h of immobilization. Between 8 and 16 h, the amount of
entrapped HSA remained constant, with only a small change in protein content of 2.5
(±0.5) mg HSA per gram support follow taking place between 16 and 40 hours.
Therefore, the procedure for entrapment was modified to limit the time for
immobilization to between 8 and 16 h. A standard procedure for the immobilization of
HSA and other proteins through the Schiff base method calls for an immobilization time
of 6 days. This rate study indicated that HSA immobilization via the entrapment method
is markedly faster than Schiff base immobilization. This represents another advantageous
aspect of the entrapment method.
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Figure 2-7.

Amount of entrapped HSA immobilized over a period of 40 h. The
conditions are given in the text. The error bars represent a range of  1
S.D.
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Effect of Protein Concentration on HSA Entrapment.
Another factor of interest was the relationship between the amount of protein
added into the reaction mixture and the resulting amount of entrapped protein. Because
the protein of interest was sterically entrapped between the surface of the silica and the
glycogen, the amount of protein entrapped should have been affected by the
concentration of protein in the reaction solution. By using different concentrations for
this protein solution, the amount of protein entrapped into hydrazide-activated silica was
examined and related to the initial protein concentration.
This relationship was examined by using 10 mg of 300Å pore size hydrazideactivated silica that was reacted with a solution containing various concentrations of HSA
and 0.20 mg of oxidized glycogen. The mixture was reacted for 12 h at 4 °C. The results
are summarized in Figure 2-8. As the concentration of HSA in the reaction mixture was
increased from 19 to 118 mg HSA per gram silica, there was a subsequent increase in the
amount of HSA that was entrapped onto the support. As larger amounts of HSA were
added, the amount of entrapped protein reached a plateau at approximately 42.9 (±0.5)
mg HSA per gram support. For all subsequent optimization studies a concentration of
100 mg HSA per gram silica was used in the reaction mixture.
Alternative Ligand Entrapment.
The method of entrapment that is described in this report is not limited to HSA
but can also be extended to other proteins and biomacromolecules. Table 2-2 shows the
results that were obtained for a series of other proteins and ligands that were entrapped in
silica with a 300 Å pore size, using the final conditions developed for work with HSA.
The ligands that were examined ranged in size from insulin (MW, 5.8 kDa) to ferritin

49

Figure 2-8.

Amount of entrapped HSA immobilized as a function of the amount of
HSA that was used for the entrapment process. The amount of added
protein was varied, while the amount of added oxidized glycogen, the
degree of oxidation and the pore size of the support (300 Å) remained
constant. The conditions are given in the text. The error bars represent a
range of  1 S.D.
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(MW, 450 kDa). It was found that ligands up to a size of at least 150 kDa (as represented
by IgG) could be successfully entrapped by this method, where the amount of entrapped
ligand was inversely related to the mass of the ligand. All of these ligands were much
lower in molecular weight than the glycogen that was used for entrapment (i.e.,
approximate MW, 104 kDa). The results fit with the previously proposed mechanism, in
which these ligands were physically contained within pockets created between the
surface of the support and the oxidized glycogen. Although there was a small amount of
ferritin immobilized by this approach, there was also a large decrease in the relative
amount of this ligand that was entrapped versus the amount that was obtained for IgG or
lower mass ligands. Thus, it was found that this approach could be used with ligands and
proteins with masses in the general range of 5.8 to 150 kDa, with some entrapment also
being noted at higher masses (up to 450 kDa).
Glycogen Oxidation Levels.
Initially the oxidation of glycogen for use in the entrapment method called for a
concentration of 88 mM periodic acid in the reaction mixture, corresponding to a 4:1
ratio of periodic acid to glycogen. These conditions lead to the oxidation of only 0.5% of
the glucose units in the glycogen molecule.18 This was within the range suggested for the
oxidation of antibody carbohydrate residues for site-specific immobilization.19
However, in this study the entrapment method used glycogen only as a means to
entrap ligands, so activity of the oxidized glycogen was not of importance.

The

following study investigated how increasing the concentrations of oxidizing agent would
affect the ability of the system to entrap HSA.
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Table 2-2.

Alternative ligands immobilized by the entrapment method.

Identity of
ligand

a

Amount of
Amount of
Ligand mass
immobilized ligand
immobilized ligand
(kDa)
(mg ligand/g support) (mol ligand/g support)a

Insulin

5.8

93 ( 2)

160 ( 3) x 10-7

Myoglobin

16.7

21 ( 3)

12 ( 2) x 10-7

Streptavidin

52.8

12.6 ( 0.5)

2.38 ( 0.01) x 10-7

Avidin

69.0

10.7 ( 0.5)

1.55 ( 0.01) x 10-7

gHSA

71.4

14.9 ( 1.4)

2.09 ( 0.19) x 10-7

IgG

150.0

15.7 ( 0.2)

1.05 ( 0.01) x 10-7

Ferritin

450.0

9.0 ( 0.8)

0.20 ( 0.01) x 10-7

Abbreviations: gHSA, glycated human serum albumin; IgG, immunoglobulin G (rabbit).

The values in parentheses represent ± 1 S.D.
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The concentration of periodic acid was expressed as a mass-to-mass ratio of
periodic acid to glycogen. This study looked at unoxidized glycogen up to a ratio of 12.5
mg periodic acid per mg glycogen, which was an approximate three-fold increase versus
the original entrapment conditions. All supports used in the previous porosity study were
also used in this comparison. The oxidation level of glycogen was the single variable; all
other reaction conditions were held constant. All porosities examined in this study used 3
mg samples of dihydrazide activated silica, a concentration of 20 mg oxidized glycogen
per gram silica, and 100 mg HSA per gram silica. The reaction mixture was mixed at 4
°C for 12 h.
The first support examined was prepared using nonporous silica. Initially, as the
oxidation level of glycogen increased the amount of entrapped HSA also increased,
reaching a maximum of 33 (± 1) mg HSA per gram support at a mass ratio of
approximately 6.5 mg periodic acid per mg of glycogen. Higher levels of oxidation
resulted in a decrease in entrapped HSA. The 1000 Å pore size support showed an
increase in entrapped HSA, which reached a maximum of 28 (± 1) mg HSA per gram
support at a mass ratio approximately 6.5 mg periodic acid per gram silica. This trend
was repeated for the 500 Å pore size support, where the amount of entrapped protein
increased to a maximum of 33 (± 2) at a mass ratio of approximately 6.5 mg periodic acid
per mg glycogen.
These three supports resulted in data that shared a similar trend. This trend could
be attributed to the complete exclusion of glycogen from pore sizes of 300 Å and
smaller.18 In supports with pore sizes of 500 Å and 1000 Å, both the glycogen and
protein have access to the pores. It can therefore be assumed that a portion of the pores
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are occupied with glycogen causing the results to look similar to that of the nonporous
support.
When the entrapment samples using 300 Å porous silica were analyzed, the
amount of entrapped HSA increased steadily over the entire analysis range. The highest
three levels of glycogen oxidation gave protein content in the range of 34.5 (± 1.5) mg
HSA per gram of support. Analysis of the 50 Å porous silica samples gave a much
different set of results. In this study, a maximum protein content of 37 (± 1) mg HSA per
gram of support was achieved early, at a mass ratio of approximately 3 mg periodic acid
per mg glycogen, followed by a decrease in protein content at higher levels of oxidation
to a protein content of 13 (± 1) mg HSA per gram of support, at 8 – 12 mg periodic acid
per mg glycogen.

Results from these four porosities were combined into one plot

presented in Figure 2-9.
The support with a porosity of 100 Å was examined further in Figure 2-10 due to
the fact that higher levels of protein were entrapped on this support compared to the other
materials. The amount of entrapped HSA increased to a maximum of 174 (± 2) mg HSA
per gram of support at a mass ratio of approximately 6.75 mg periodic acid per mg
glycogen. Higher levels of oxidation resulted in only a slight decrease in protein content,
with the highest level of oxidation entrapping 158 (± 2) mg HSA per gram of support.
These levels of protein are roughly four times the protein content of traditional HPAC
supports containing HSA that has been immobilized via covalent techniques.17
Both the 300 Å and 100 Å supports showed a steady amount of entrapped protein
after the maximum, this may be due to the ability of higher levels of oxidation to force
the HSA down into the pores and therefore increase the protein content.
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Figure 2-9.

Amount of entrapped HSA as a function of the mass ratio of periodic acid
to glycogen that was used for glycogen oxidation in the initial step of the
entrapment process. The porosity of the supports ranged from a pore size
of 50Å to nonporous (NP) glass beads. The conditions are given within
the text. The error bars represent a range of  1 S.D.
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Figure 2-10. Amount of entrapped HSA as a function of the mass ratio of periodic acid
to glycogen that was used for glycogen oxidation in the initial step of the
entrapment process on a pore size of 100 Å silica support. The conditions
are given within the text. The error bars represent a range of  1 S.D.
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Results for the 50 Å support do not follow this trend, possibly because the pores are too
close in size to the HSA, causing steric interference.
A study using 100 Å pore size silica and AGP as the model ligand was also
conducted. All parameters were consistent with those used for the entrapment of HSA in
100 Å porous supports. The results for this study can be seen in Figure 2-11. The
amount of entrapped AGP increased to a maximum of 144 (± 8) mg AGP per gram of
support at a mass ratio of approximately 6.75 mg periodic acid per mg glycogen. Higher
levels of oxidation resulted in only a slight change in protein content, with the highest
level of oxidation entrapping 135 (± 3) mg AGP per gram of support. This high protein
content combined with the retention of all protein activity when immobilizing with the
entrapment method would produce supports with extremely high binding capacities.
High Capacity Supports.
The high protein content achieved in the previous study indicated that it could be
possible to make high capacity HPAC supports using the entrapment method. This
optimization study looked at both HSA and IgG as model ligands and employed 100 Å
porous silica as the support material.

The glycogen was oxidized using a mass ratio of

7.95 mg periodic acid per mg glycogen and was added to the reaction mixture at a
concentration of 20 mg glycogen per gram silica. In order to determine the maximum
amount of ligand that could be entrapped, the concentration of HSA was varied from 25
to 400 mg initial HSA per gram silica. Figure 2-12 shows the results for the entrapped
HSA under these reaction conditions. The amount of entrapped HSA increased directly
with the amount of initial HSA in the reaction mixture up to a value of 200 mg of initial
HSA per gram silica, which indicated that efficient HSA immobilization was present.
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Figure 2-11. Amount of entrapped AGP as a function of the mass ratio of periodic acid
to glycogen that was used for glycogen oxidation in the initial step of the
entrapment process on a100 Å pore size silica support. The conditions are
given within the text. The error bars represent a range of  1 S.D.
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A maximum of 211 (± 9) mg entrapped HSA per gram support, was reached at 400 mg
initial HSA per gram silica, but was similar to values obtained at 200 and 300 mg initial
HSA per gram silica.
Similar results and trends to those for HSA were also seen in the entrapment of
IgG under the same reaction conditions (Figure 2-13). The amount of entrapped IgG
increased steadily up to 200 mg IgG per gram silica. Concentrations above this value
produced relatively similar amounts of immobilized IgG, hovering around 80 mg
entrapped IgG per gram of support.
Although the upper concentrations of both ligands achieved a high ligand content,
a considerable portion of the ligand in the reaction mixture was not immobilized – less
than 70% for HSA entrapment and less than 40% for the entrapment of IgG. This will be
something to take into consideration when this method is adapted for use with the larger
quantities of silica required to pack HPAC columns.

Conclusions
This chapter described the preparation of glycogen-capped hydrazide supports for
the entrapment of proteins and other ligands. In this approach, the silica support was first
activated to contain hydrazide groups.

The hydrazide-activated support was then

incubated under slightly acidic pH conditions with a solution containing the protein or
binding agent of interest and an oxidized form of glycogen. While aldehyde groups on
the oxidized glycogen formed a stable covalent bond with the hydrazide groups, the
soluble binding agent was entrapped in the support.
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Figure 2-12. Amount of entrapped HSA as a function of the concentration of HSA in
the reaction mixture. This study was done with 100 Å pore size silica and
a periodic acid ratio of 7.95 mg H5IO6/g glycogen. The conditions are
given within the text. The error bars represent a range of  1 S.D.
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Figure 2-13. Amount of entrapped IgG as a function of the concentration of IgG in the
reaction mixture. This study was done with 100 Å pore size silica and a
periodic acid ratio of 7.95 mg H5IO6/g glycogen. The conditions are given
within the text. The error bars represent a range of  1 S.D.
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Frontal analysis was used to determine Ka values for both S-warfarin (a probe for
Sudlow site I) and L-tryptophan (a probe for Sudlow site II) with the entrapped HSA.
The binding capacity of the support was also determined by using frontal analysis. The
binding capacity was closely related to the overall protein content of the supports as
determined by a micro BCA protein assay, and translated to a specific activity of
essentially 100% for both tested analytes. This study revealed that both major binding
sites of the entrapped HSA were active and available for binding.
The entrapment method was then optimized to achieve maximum protein content
through the variation of several different reaction components and procedures. The
method was tested on five silica supports with varying porosities, as the concentrations of
oxidized glycogen and HSA in the reaction mixtures were varied, as well as the time
allowed for the reaction to take place. Other components tested were the ability of the
entrapment method to work with ligands other than HSA, and the effect of increasing the
oxidation level of the glycogen on the amount of immobilized ligand.
This alternative method of entrapment allows for physical containment of a ligand
in a high performance support material. The resulting entrapped ligand is not only
accessible to small analytes, but also retains essentially 100% of its binding activity.
Association equilibrium constants for the chosen system were in good agreement with
previously reported values. After optimization of the reaction conditions, a greater than
five-fold increase in immobilized protein content was achieved versus traditional
covalent immobilization techniques, indicating the possibility of the production of high
capacity columns for HPAC. This novel immobilization technique provides the ability to
examine ligands that mimic native behavior using the speed and precision of HPAC.
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Further studies can be done to examine how the optimized parameters affect the ability of
drugs to access and bind to the entrapped ligand.
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CHAPTER 3:
THE EFFECT OF VARYING THE OXIDATION LEVEL
OF GLYCOGEN IN THE PREPARATION
OF ENTRAPPED HSA SUPPORTS

Introduction
Drug interactions with serum proteins are important in determining the activity,
transport, excretion and metabolism of many pharmaceutical agents in the body. Human
serum albumin (HSA), the most abundant protein in serum, is commonly involved in this
reversible drug-protein binding. HSA is known to bind to a large number of drugs,
hormones and other small analytes in the body.1-3 Due to the widespread occurrence of
these interactions, numerous analytical techniques, including high performance affinity
chromatography (HPAC), have been employed to study the interaction of drugs with
HSA.3-6 It has been previously shown that HPAC supports containing immobilized HSA
can effectively represent drug-binding involving soluble HSA.7
In Chapter 2 a new noncovalent immobilization technique was introduced as an
alternative to traditional covalent immobilization. Part of this optimization examined the
effect of glycogen oxidation levels on the amount of entrapped HSA. This study was
conducted by using various amounts of periodic acid for the oxidation of glycogen during
the initial steps of the entrapment method.

This glycogen was then used to make

entrapped HSA supports with several levels of oxidized glycogen as the capping agent.
This chapter will examine the binding of several analytes as a function of the level
of glycogen oxidation. These analytes will also include R-warfarin and L-tryptophan,
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which are common site-selective probes for HSA. R-warfarin, an anticoagulant, binds to
Sudlow site I, while L-tryptophan, an essential amino acid, binds to Sudlow site II.8,9
The structures of these compounds can be seen in Figure 3-1. These probe compounds
will be injected at various flow rates on to each column to determine if the ability of the
drug to reach the entrapped protein is effected by changes in the flow rate.
Measurements of the protein content and retention factor will be used to examine the
interactions of drugs to the immobilized HSA and to determine the effect of the level of
glycogen oxidation on the binding capabilities of the column. The efficiency for each
column will also be investigated through the use of band broadening measurements to
determine plate heights. Finally, the entrapment method will be compared to the Schiff
base immobilization method through the examination of the retention of a variety of
injected analytes on columns that are prepared by these two methods.

Experimental
Reagents.
The p-periodic acid (periodic acid reagent, or H5IO6), glycogen (from bovine
liver), HSA (Cohn fraction V, 99% globulin free, 99% fatty acid free), R-warfarin, Swarfarin, L-tryptophan, acetohexamide, gliclazide, tolbutamide, monobasic and dibasic
potassium phosphate salts, sodium chloride and sodium acetate were purchased from
Sigma-Aldrich (St. Louis, MO). The Nucleosil Si-300 silica (300 Å nominal pore size, 7
m diameter) was purchased from Macherey-Nagel (Düren, Germany). Reagents for the
micro bicinchoninic acid (BCA) protein assay were purchased from Pierce (Rockford,
IL). Other chemicals were of the purest grades available. The Econo-Pac 10 DG
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Figure 3-1.

Structures of R-warfarin and L-tryptophan.
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disposable 30 x 10 mL desalting columns were purchased from Bio-Rad Laboratories
(Hercules, CA). All solutions were prepared using water from a NANOpure purification
system (Barnstead, Dubuque, IA) and filtered with a 0.20 µm GNWP nylon membrane
from Millipore (Billerica, MA).
Apparatus.
The chromatographic system consisted of a Jasco PU-980i intelligent HPLC
isocratic pump (Tokyo, Japan), a Rheodyne Advantage PF ten-port valve (Cotati, CA),
and a Jasco UV-975 UV/Vis detector.

Data were collected using an interface and

software from National Instruments (Austin, TX). The temperature of the columns and
mobile phases was controlled using a PolyScience circulating VWR circulating water
bath (Buffalo Grove, IL) and a water jacket from Alltech. All columns were packed
using an HPLC column slurry packer from Alltech. Peakfit v.4.12 and an exponentiallymodified Gaussian curve fit were used to determine the central moments of all eluting
peaks.
Methods.
Nucleosil Si-300 was converted into a dihydrazide-activated form according to a
previously-established procedure.10

Optimized entrapment conditions established in

Chapter 2 were used to prepare columns containing entrapped HSA and control
supports. Three separate oxidized glycogen solutions were prepared in a pH 5.0 buffer
containing 20 mM sodium acetate and 15 mM sodium chloride. Each 4.0 mL solution
was prepared by dissolving various amounts of periodic acid and 17 mg of glycogen from
bovine liver in the aforementioned buffer. The different samples will be referred to by
the mass ratio of periodic acid to oxidized glycogen used in the initial step of the
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oxidation. The three samples contained the following amounts of periodic acid: HSA
3.95, 67 mg; HSA 7.95, 135 mg; and HSA 12.05, 205 mg – where the number
designations of 3.95, 7.95 and 12.05 refer to the ratio of mg periodic acid to mg
glycogen.
Each solution was covered in aluminum foil – due to the light sensitivity of
periodic acid – and allowed to shake at room temperature for 12-24 h. After oxidization,
each glycogen solution was purified using a separate Econo-Pac 10DG disposable
desalting column and pH 5.0, 0.10 M potassium phosphate buffer. This process was done
by first removing the upper cap of the column and decanting the excess storage buffer.
The next step was a buffer exchange via the addition of 10.0 mL of pH 5.0, 0.10 M
potassium phosphate buffer to the column. Next, 3.3 mL of the oxidized glycogen
sample were allowed to pass through the column, followed by an addition of 4.0 mL of
potassium phosphate buffer to elute the oxidized glycogen.

The larger glycogen

molecules eluted from the column during this step, while the smaller periodic acid
molecules took much longer to pass through the column matrix. Each final purified
oxidized glycogen solution had a concentration of 4.2 mg/mL in a volume of
approximately 4.0 mL. These solutions were stored at 4 °C.
Three entrapped HSA supports were prepared under the same immobilization
conditions. To create the HSA-3.95 entrapped support, 80 mg of dihydrazide-activated
silica was combined with 160 µL of a 50 mg/mL stock solution of protein prepared in pH
5.0, 0.10 M potassium phosphate buffer. This mixture was sonicated under vacuum for
15 min to ensure the proper mixing of the silica and protein. A 380 µL portion of the
specified oxidized glycogen was added, and the mixture was shaken at room temperature
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for 12 h. During the final hour of the reaction, 200 µL of a 2 mg/mL oxalic dihydrazide
solution in the same buffer was added to the reaction mixture to cover any remaining
aldehyde groups on the silica support. After immobilization, the support was washed
several times with pH 7.4, 67 mM potassium phosphate buffer. A control support was
also prepared using the specified oxidized glycogen solution, with the addition of a 160
µL aliquot of potassium phosphate buffer in place of the protein solution. Binding of an
analyte to the prepared control support was used to monitor non-specific interactions.
This procedure was repeated for the preparation of the HSA-7.95 support and the HSA12.05 support.
Another 80 mg portion of Nucleosil Si-300 was converted to diol-bonded silica,
and HSA was immobilized to this support by the Schiff base method according to
previously-published procedures.11,12

A control support was also made using this

method, without the addition of HSA.
The protein content of the entrapped HSA and Schiff base HSA supports was
determined by using a micro BCA assay, with soluble HSA being used to create a
standard curve and the control support being used as the blank. The protein content,
determined in mg HSA per gram support for all supports were as follows: HSA-3.95
support, 25.2 (± 0.5); HSA-7.95 support, 37 (± 1); HSA-12.05 support, 36 (± 1); and 39
(± 2) for the Schiff base HSA support. All supports were downward slurry-packed into
separate 1.0 cm  2.1 mm I.D stainless steel columns at 4000 psi using pH 7.4, 67 mM
potassium phosphate buffer as the packing solution. All columns were stored at 4°C in
the packing solution.
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Zonal elution studies were performed on all four sets of columns using two wellcharacterized probe compounds for HSA: R-warfarin, which is known to bind to Sudlow
site I, and L-tryptophan, which is known to bind to Sudlow site II. Binding of drugs to
the entrapped HSA-7.95 column and the Schiff base HSA column were then examined in
further detail using four additional analytes: S-warfarin, acetohexamide, gliclazide and
tolbutamide. All sample solutions for the chromatographic studies were prepared in pH
7.4, 67 mM potassium phosphate buffer. Stock sample solutions with a concentration of
30 µM R-warfarin or S-warfarin and a concentration of 100 µM L-tryptophan,
acetohexamide, gliclazide or tolbutamide were prepared in pH 7.4, 67 mM potassium
phosphate buffer. The stock solutions were diluted with this pH 7.4 buffer to give 10 µM
working samples of all analytes.
A 20 µL volume of each sample was injected onto the HSA columns and control
columns in triplicate at 37 °C in the presence of pH 7.4, 67 mM potassium phosphate
buffer. Flow rates of 0.1-1.0 mL/min were used to examine the binding of each analyte
to the entrapped HSA columns or Schiff base HSA column. The void time of each
column was determined by making triplicate 20 µL injections of 25 µM sodium nitrate in
the presence of pH 7.4, 67 mM potassium phosphate buffer at each sampled flow rate.
The void time of the system was determined by repeating these injections of sodium
nitrate on a zero-volume union. Peakfit v.4.12 and an exponentially-modified Gaussian
curve fit were used to determine the central moments of all eluting peaks.
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Results and Discussion
Zonal elution studies of analyte retention on entrapped HSA columns
Initial zonal elution studies using the probe compounds R-warfarin and Ltryptophan were performed on the HSA-3.95, HSA-7.95, HSA-12.05 columns and the
Schiff base HSA column. The retention factor (k) was measured for each analyte at flow
rates of 0.10, 0.25, 0.50, 0.75 and 1.00 mL/min on each column. The value of k was
calculated according to Equation 3-1, where tR is the retention time of the analyte and tM
is the void time of the column.

k

(t R  t M )
tM

(3-1)

Figure 3-2 shows how varying the flow rate affected the retention factors measured for
R-warfarin and L-tryptophan on each column. These retention factors were normalized
by dividing k by the measured total protein content for each support. This allowed for a
more accurate comparison of retention factors between columns. Each column showed
good consistency in retention factor across all flow rates, indicating that access to either
Sudlow site I or Sudlow site II on the immobilized HSA was not hindered by an increase
in flow rate on these columns.
As the oxidation level of the glycogen was increased, an initial increase in protein
content was seen in going from column HSA-3.95 to column HSA-7.95, followed by a
leveling off with column HSA-12.05. This trend agrees with data collected for the
optimization of glycogen oxidation for 300 Å pore size silica in Chapter 2. The direct
relationship between retention factor and protein content can been seen in Equation 3-2,
'

k

( K a m Ltotal )
Vm

(3-2)
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Figure 3-2.

Normalized retention factors determined at various flow rates for the
HSA-3.95, HSA-7.95, HSA-12.05, and Schiff base immobilized HSA
supports for (a) R-warfarin and (b) L-tryptophan. All measurements were
adjusted for nonspecific binding through the use of a control support.
Other experimental conditions are given in the text.
represent ± 1 S.D.

The error bars
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Table 3-1.

Measured binding capacities and retention factors for R-warfarin and Ltryptophan on the HSA-3.95, HSA-7.95, HSA-12.05 and the Schiff base
HSA supports. All measurements were adjusted for nonspecific binding
through the use of a control support.

a

R-warfarin

Protein content
(nmoles)

Retention
factor (k)

Normalized retention factor
k/(protein content)a

HSA-3.95

5.6 (± 0.4)

52 (± 1)

2.07 (± 0.07)

HSA-7.95

8.2 (± 0.2)

84.7 (± 0.5)

2.30 (± 0.07)

HSA-12.05

8.1 (± 0.2)

27.7 (± 0.2)

0.73 (± 0.2)

Schiff Base

8.7 (± 0.4)

41.4 (± 0.3)

1.14 (± 0.06)

L-tryptophan

Protein content
(nmoles)

Retention
factor (k)

Normalized retention factor
k/(protein content)a

HSA-3.95

5.6 (± 0.4)

4 (± 1)

0.14 (± 0.07)

HSA-7.95

8.2 (± 0.2)

5.7 (± 0.3)

0.16 (± 0.04)

HSA-12.05

8.1 (± 0.2)

2.2 (± 0.1)

0.06 (± 0.02)

Schiff Base

8.7 (± 0.4)

3.5 (± 0.4)

0.10 (± 0.06)

These normalized retention factors were calculated by dividing the listed retention

factors by a measured total protein content for the given support in units of mg HSA/g
support. The values in parentheses represent a range of ± 1 S.D.
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where Vm is the void volume of the column and Ka’ and mLtotal are the global association
constant (the average of Ka1 and Ka2) and the moles of total active protein in the column.
Table 3-1 presents the measured protein contents and retention factors for all supports
that were analyzed. The data for columns HSA-3.95 and HSA-7.95 were in agreement
with Equation 3-2, but a significant deviation was seen in the data for column HSA12.05. The protein content was statistically equal to the value for HSA-7.95, but a
decrease of approximately three-fold in retention was seen between the two columns for
both R-warfarin and L-tryptophan. Because the only varied parameter between the two
supports was the amount of periodic acid used in the oxidation of glycogen, this decrease
in retention factor was most likely due to overoxidation of the glycogen, blocking access
to some of the entrapped protein.
Overoxidation has been seen with the use of high periodic acid concentrations
during antibody oxidation. This can occur when diol groups are oxidized past aldehyde
groups to carboxylic acids, or when cross-linking occurs between oxidized
glycoproteins.13,

14

Another effect of overoxidation is decreased solubility.

After

glycogen oxidation, any remaining solution was stored at 4 °C Samples HSA-3.95 and
HSA-7.95 remained in solution, while sample HSA-12.05 produced a white precipitate
within a few days following preparation. This observation is consistent with previouslyreported observations of antibody precipitation after oxidization with high levels of
periodic acid13. In this study the overoxidation of glycogen appeared to inhibit the
accessibility of an analyte for the entrapped HSA.
Although the protein content of the HSA-7.95 column and the Schiff base HSA
column were similar, the entrapment column had an increased value for the retention
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factor. As seen in Equation 3-2, the retention factor is directly related to the protein
content, so it would follow that similar protein content would result in similar values for
retention factor. However, differences in specific activity between the two types of
immobilization can account for the discrepancy in retention factor. This concept was
examined further through the use of a wider variety of injected analytes, and will be
discussed later in this chapter.
Band broadening for analytes on entrapped HSA columns
Band broadening is another parameter that can be used in zonal elution studies
with HPAC to obtain information about the interaction between an analyte and an
immobilized ligand.5,7 In this type of study, an affinity column is viewed as being
comprised of a series of equal-sized regions as represented by (N), the number of
theoretical plates. Each theoretical plate represents a single interaction between the
analyte and the stationary phase. The distance along the column that makes up a single
theoretical plate is represented by the plate height (H). These two terms are related to
one another through the total length of the column (L), where H = L/N.7, 15 Plate height
can be used as an indication of column efficiency, where H decreases with increasing
efficiency. The value of H is related to the width, or the second moment (σ2) of a peak.
In this type of study, measurements are taken for injections at several different flow-rates.
Plate height values can then be calculated according to Equation 3-3, where HR
HR 

L 2 R
tR

2

(3-3)

is the total plate height measured for the column, L is the column length (in cm), σ2R is
the second moment of the retained analyte peak, and tR is the analyte’s retention time.
The plate height contribution of the stationary phase is found by taking the difference
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between the total plate height measured for the analyte on the HSA column and the plate
height measured for a control column.7
Figure 3-3 shows the values for plate height that were obtained for the injection
of 10 µM R-warfarin for all supports studied. These values were used as a means for
comparison of column efficiency. Over the range of linear velocities 0.1 – 0.8 cm/s the
plate height values for the individual entrapment-based columns stayed consistent,
indicating that there was no loss in efficiency as the flow rate was increased up to 0.8
cm/s. When the entrapped HSA columns were compared to each other, the efficiency
decreased as the oxidation level of glycogen was increased. The HSA-3.95 and HSA7.95 supports had similar values for the plate height, ranging from 0.010 to 0.018 (±
0.001). The HSA-12.05 support had a much higher values for plate height, with an
average value of 0.057 (± 0.001). Similar results were noted for of L-tryptophan. This
reduction in column efficiency at high levels of oxidation can most likely be attributed to
the overoxidation of glycogen and slower mass transfer for the injected analytes on the
entrapped HSA support. This analysis further supports the hypothesis that overoxidation
of glycogen can limit the accessibility of an analyte to reach the entrapped HSA.
Correlation study
For a comparison between the entrapment and Schiff base immobilization
methods, injections of four additional analytes were made: S-warfarin, acetohexamide,
gliclazide and tolbutamide. The supports used for this comparison were the Schiff base
HSA column and the HSA-7.95 entrapped column. The HSA-7.95 column was chosen
for this study because it had good efficiency and similar protein content to the Schiff base
HSA column. Correlation charts for the injection of six analytes on these columns are
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Figure 3-3.

Plate height plots obtained for 20 µL injections of R-warfarin on the
entrapped HSA columns. Other experimental conditions are given in the
text. The error bars represent ± 1 S.D.
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Figure 3-4.

Correlation plots between the normalized retention factors for various
drugs on the entrapped HSA-7.95 column and the Schiff base immobilized
HSA column.

Conditions can be found in the text.

coefficient for this plots was 0.940 (n = 6).

The correlation

Normalized k (Entrapment)

0.00
0.00

0.50

1.00

1.50

2.00

2.50

3.00

1.00

Norm alized k (Schiff Base)

0.50

1.50

88

89
shown in Figure 3-4. Each value shown is the average normalized retention factor for
triplicate injections at five different flow rates. The plot of entrapment vs. Schiff base
results had a slope of 1.6946. This indicated that the entrapment method results in an
approximately a 70% higher retention factor when compared to the Schiff base method,
further illustrating the effect of specific activity on the retention factor.

Conclusions
This chapter used HPAC zonal elution studies to examine the changes in analyte
binding as a function of the level of initial glycogen oxidation for entrapped HSA. Three
levels of glycogen oxidation were used to prepare entrapped HSA supports. Zonal
elution studies with R-warfarin and L-tryptophan showed that retention factors were
consistent over a range of flow rates, but the value of the retention factor was effected by
the level of oxidized glycogen used to prepare the supports. The entrapped HSA-12.05
support did not have retention factors consistent with its measured protein content. This
indicated that the analyte was not fully able to access the entrapped protein, due to
possible glycogen overoxidation.

Normalized retention factors for the other two

entrapped columns were higher than the values reported for the Schiff base immobilized
HSA support. The relationship between retention and protein content suggests that a
larger portion of the entrapped HSA was active compared to the HSA in the Schiff base
column.

This fits with previously-established data for the specific activity of each

method.
This work also investigated the efficiency of each column as a function of
glycogen oxidation through a determination of plate heights. The values for the plate
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height remained consistent throughout the span of sampled flow rates but increased as the
oxidation level of glycogen increased. The entrapped HSA-12.05 column showed a
significant decrease in efficiency compared to the other entrapped supports, reinforcing
the idea that the analyte’s ability to interact with entrapped protein was inhibited by the
highly oxidized glycogen in this support.
The results of this work indicate that entrapment supports made with glycogen
that has undergone a moderate level of oxidation can be used in place of covalently
immobilized supports for the analysis of drug-protein interactions. A relatively small 1.0
cm column contains a similar protein content to a comparable Schiff base column, but
higher values of retention can be achieved, due to the presence of essentially 100%
protein activity. The entrapped HSA column also shows consistent efficiency at common
HPLC flow rates.
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CHAPTER 4:
THE USE OF ENTRAPMENT TO EXAMINE THE EFFECT OF GLYCATION ON
THE BINDING OF SEVERAL DRUGS TO HUMAN SERUM ALBUMIN

Introduction
Human serum albumin (HSA), serves as an important carrier protein, is the most
abundant protein in human plasma.1, 2 This protein has two major binding sites, Sudlow
site I and Sudlow site II.3,

4

The binding of drugs to HSA can be affected by many

factors.2 This chapter will focus on the effects of glycation on analyte binding, a process
especially prevalent in individuals with diabetes.2, 5 The glycation process is thought to
alter the secondary and tertiary structure of HSA. Because some of the glycation sites are
near Sudlow sites I and II, the glycation process can potentially alter the overall binding
affinity for analytes to HSA.5-7
The first portion of this study will compare the binding of R-warfarin and Ltryptophan (structures seen in Figure 4-1) to HSA versus glycated HSA (gHSA) using
the entrapment immobilization method. Warfarin and L-tryptophan are often used as
site-selective analytes for Sudlow sites I and II, respectively.8 This study will then be
extended to examine how the binding of three sulfonylureas were affected by the
glycation of HSA. Sulfonylureas, including acetohexamine, gliclazide and tolbutamide,
are a class of drugs commonly used to treat type II, or non-insulin dependent diabetes.9, 10
The structures for these analytes can be seen in Figure 4-2. It has been shown that the
three sulfonylureas examined in this study bind to both major sites of HSA, as
characterized by HPAC and covalently immobilized HSA.11, 12
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Figure 4-1.

Structures of R-warfarin and L-tryptophan.
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Figure 4-2.

Structures of the sulfonylurea drugs used in this study.

96

97
This chapter will use the entrapment method for the immobilization of both HSA
and gHSA. These entrapped supports will be used in zonal elution to explore the effects
of glycation on the binding of the aforementioned target analytes to entrapped HSA and
entrapped gHSA.

Experimental
Reagents.
The p-periodic acid (periodic acid reagent, or H5IO6), glycogen (from bovine
liver), HSA (Cohn fraction V, 99% globulin free, 99% fatty acid free), glycated HSA
(95% lyophilized, lot no. 115K6108), R-warfarin, L-tryptophan, acetohexamide,
gliclazide, tolbutamide, monobasic and dibasic potassium phosphate salts, sodium
chloride and sodium acetate were purchased from Sigma-Aldrich (St. Louis, MO). The
Nucleosil Si-300 silica (300 Å pore size, 7 micron particle diameter) was purchased from
Macherey-Nagel (Düren, Germany). Reagents for the micro bicinchoninic acid (BCA)
protein assay were purchased from Pierce (Rockford, IL). Other chemicals were of the
purest grades available. The Econo-Pac 10 DG disposable 30 x 10 mL desalting columns
were purchased from Bio-Rad Laboratories (Hercules, CA). All solutions were prepared
using water from a NANOpure purification system (Barnstead, Dubuque, IA) and filtered
with a 0.20 µm GNWP nylon membrane from Millipore (Billerica, MA).
Apparatus.
The chromatographic system consisted of a Jasco PU-980i intelligent HPLC
isocratic pump (Tokyo, Japan), a Rheodyne Advantage PF ten-port valve (Cotati, CA),
and a Jasco UV-975 UV/Vis detector. The detection wavelengths were as follows: 205
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nm, sodium nitrate; 226 nm, gliclazide; 248 nm, acetohexamide, 250 nm, tolbutamide;
280 nm, L-tryptophan, and 304 nm, R-warfarin. Data were collected using an interface
and software from National Instruments (Austin, TX). The temperature of the columns
and mobile phases was controlled using a PolyScience circulating VWR circulating water
bath (Buffalo Grove, IL) and a water jacket from Alltech. All columns were packed
using an HPLC column slurry packer from Alltech. The chromatographic data were
analyzed using Peakfit 4.12 (Jandel Scientific Software, San Rafael, CA).
Methods.
Nucleosil Si-300 was converted into a dihydrazide-activated form according to
previously-established procedures.13

Optimized entrapment conditions established in

Chapter 2 were used to prepare columns containing entrapped HSA, entrapped glycated
HSA, and control supports. The oxidation of glycogen was carried out in a pH 5.0 buffer
containing 20 mM sodium acetate and 15 mM sodium chloride. A 4.0 mL solution was
prepared by dissolving 135 mg of periodic acid and 17 mg of glycogen from bovine liver
in the aforementioned buffer. This solution was covered in aluminum foil – due to the
light sensitivity of periodic acid – and allowed to shake at room temperature for 12 – 24
h. After oxidization, the glycogen was purified using an Econo-Pac 10DG disposable
desalting column and pH 5.0, 0.10 M potassium phosphate buffer. This process was done
by first removing the upper cap of the column and decanting the excess storage buffer.
The next step was a buffer exchange via the addition of 10.0 mL of pH 5.0, 0.10 M
potassium phosphate buffer to the column. Next, 3.3 mL of the oxidized glycogen
sample were allowed to pass through the column, followed by a volume of 4.0 mL of
potassium phosphate buffer to elute the oxidized glycogen.

The larger glycogen
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molecules eluted from the column during this step, while the smaller periodic acid
molecules took much longer to pass through the column matrix. The resulting purified
oxidized glycogen solution had a concentration of 4.2 mg/mL with a final volume of
approximately 4.0 mL. This solution was stored at 4 °C.
Both HSA and gHSA supports were prepared under the same immobilization
conditions. A 50 mg/mL stock solution of protein was prepared with pH 5.0, 0.10 M
potassium phosphate buffer. To create the entrapped support, 80 mg of dihydrazide
activated silica was combined with 160 µL of the protein solution. This mixture was
sonicated under vacuum for 15 min to ensure the proper mixing of the silica and protein.
A 380 µL portion of the purified oxidized glycogen was added, and the mixture was
shaken at room temperature for 12 h. During the final hour of the reaction, 200 µL of a 2
mg/mL oxalic dihydrazide solution in the same buffer was added to the reaction mixture
to cover any remaining aldehyde groups on the silica support. After immobilization, the
support was washed several times with pH 7.4, 67 mM potassium phosphate buffer. A
control support was also prepared through the addition of a 160 µL aliquot of potassium
phosphate buffer in place of the protein solution. Binding of an analyte to this support
was used to monitor non-specific interactions. The protein content of the entrapped HSA
and gHSA supports was determined using a micro BCA assay, with soluble HSA or
gHSA being used to create a standard curve and the control support being used as a
blank. The HSA support was found to contain 37 (± 1) mg HSA per gram support, and
the gHSA support contained 32 (± 2) mg gHSA per gram support.
All supports were downward slurry-packed into separate 1.0 cm  2.1 mm I.D
stainless steel columns at 4000 psi using pH 7.4, 67 mM potassium phosphate buffer as
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the packing solution. All columns were stored at 4 °C in the packing solution. All
sample solutions for the chromatographic studies were prepared in pH 7.4, 67 mM
potassium phosphate buffer. Stock sample solutions with a concentration of 30 µM Rwarfarin and a concentration of 100 µM L-tryptophan, acetohexamide, gliclazide or
tolbutamide, were prepared in pH 7.4, 67 mM potassium phosphate buffer. The stock
solutions were diluted with this pH 7.4 buffer to give 10 µM working samples of all
analytes.
A 20 µL volume of all samples was injected onto the entrapped HSA column,
entrapped gHSA column and control column in triplicate at 37 °C in the presence of pH
7.4, 67 mM potassium phosphate buffer. Flow rates of 0.1-1.0 mL/min were used to
examine the binding of each analyte to the protein of interest. The void time of each
column was determined by making triplicate 20 µL injections of 25 µM sodium nitrate in
the presence of pH 7.4, 67 mM potassium phosphate buffer at all sampled flow rates.
The void time of the system was determined by repeating these injections of sodium
nitrate on a zero-volume union. Peakfit v.4.12 and an exponentially-modified Gaussian
curve fit were used to determine the central moments of all eluting peaks.

Results and Discussion
Initial Zonal Elution Studies of Entrapped HSA and Entrapped gHSA.
Affinity chromatography has been shown to be a useful tool to examine the
overall affinity of drugs to immobilized proteins such as HSA.14 Zonal elution studies
can be used to determine the retention factor (k), which can then be used to calculate the
global association equilibrium constant (Ka’) of the analyte. Ka’ is an average of the
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association equilibrium constants for both the high and low affinity binding sites.
Equation 4-1 shows how the retention factor is related to the Ka’ for an injected analyte
with an immobilized protein, where mL is the moles of total moles of active binding sites
in the column and VM is the column void volume.15, 16
'

(K m
)
k  a Ltotal
Vm

(4-1)

Initially, the retention of R-warfarin and L-tryptophan on entrapped HSA and entrapped
gHSA columns was studied by performing zonal elution. These analytes were chosen for
this optimization, as they are often used as site-selective probes for Sudlow sites I and II,
respectively. Figure 4-3 shows how varying the flow rate affected the retention factors
measured for these two analytes. The consistency of the retention factors across all flow
rates examined indicated that altering the flow rate did not hinder access to either Sudlow
sites I and II by the injected analytes. The ability to use higher flow rates made it
possible to decrease the analysis time needed to obtain retention factors on the 1.0 cm 
2.1 mm I.D. entrapped protein columns.
Table 4-1 summarizes the average retention factors that were measured for each
of the tested drugs over the range of sampled flow rates on both the entrapped HSA and
entrapped gHSA columns. For a more accurate comparison, the retention factors were
normalized by dividing these values by the measured total protein content in mg protein
per gram support. Normalized retention factors for R-warfarin were relatively consistent
between the entrapped HSA and the entrapped gHSA column. The calculated Ka values
for R-warfarin ranged from 2.9 x 105 M-1 to 3.1 x 105 M-1, with a relative precision of
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Figure 4-3.

Retention factors measured at various flow rates on the entrapped HSA
and the entrapped gHSA columns for (a) R-warfarin and (b) L-tryptophan.
Other experimental conditions are given in the text.
represent ± 1 S.D.

The error bars
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Table 4-1.

Retention and calculated association equilibrium constants for R-warfarin
and L-tryptophan on entrapped HSA and glycated HSA (gHSA) columns.

HSA

Retention
factor (k)

Normalized retention factor
k/(protein content)a

Ka (M-1)

R-warfarin

84.7 (± 0.5)

2.30 (± 0.03)

2.9 (± 0.2) x 105

L-tryptophan

5.7 (± 0.2)

0.16 (± 0.04)

1.9 (± 0.3) x 104

gHSA

Retention
factor (k)

Normalized retention factor
k/(protein content)a

Ka (M-1)

R-warfarin

78.5 (± 0.8)

2.46 (± 0.06)

3.1 (± 0.3) x 105

L-tryptophan

14.22 (± 0.03)

0.45 (± 0.07)

5.6 (± 0.2) x 104

The values in parentheses represent a range of ± 1 S.D.
a

These normalized retention factors were calculated by dividing the listed retention

factors by a measured total protein content for the given supports of 37 (± 1) mg HSA per
gram support or 32 (± 2) mg glycated HSA per gram support.
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± 7-10%. These results did not show any significant variation between the entrapped
HSA and the entrapped gHSA columns, with Ka values for R-warfarin within ± 1 S.D. of
one another.

These results indicated that the glycation of HSA did not have an

observable effect on the binding of R-warfarin. These findings are consistent with
previously- reported results for the effect of glycation on Sudlow site I.8 The range of Ka
values for R-warfarin was slightly higher than the previously-reported value of 2.5 – 3.0 x
105 M-1 for Schiff base immobilized HSA.8, 17
Unlike the retention of R-warfarin, the retention of L-tryptophan was affected by
the glycation of HSA. The normalized retention factor for L-tryptophan on the entrapped
gHSA column was approximately three times higher than the analyte’s normalized
retention factor for entrapped HSA. The value of Ka increased by the same factor, from
1.9 x 104 M-1 for entrapped HSA to 5.6 x 104 M-1 for entrapped gHSA. These results
indicated that the glycation of HSA affected the binding of L-tryptophan to Sudlow site
II, consistent with recently-published results.17 While no major glycation sites occur in
close proximity to Sudlow site II, it has been suggested that small amounts of glycation
alter the tertiary structure of HSA, causing local unfolding near the binding site.7 The
value of Ka for L-tryptophan on the entrapped HSA column was slightly higher than the
previously-reported value of 1.1 (± 0.3) x 104 M-1 for Schiff base immobilized HSA.18
The discrepancies in Ka values can possibly be attributed to the increased specific
activity of the entrapment method as compared to the Schiff base method.

When

calculating the association equilibrium constant from retention factor data, the value of Ka
is directly related to the value of mL. Essentially 100% of the total protein content (mL) is
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Figure 4-4.

Retention factors measured at various flow rates on the entrapped HSA
and the entrapped gHSA columns for (a) acetohexamide, (b) gliclazide
and (c) tolbutamide. Other experimental conditions are given in the text.
The error bars represent ± 1 S.D.
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active when using the entrapment method, while immobilization through the Schiff base
method results in a typical specific activity of up to 67%.17
Zonal Elution Studies of Additional Analytes.
This study was extended to include acetohexamide, gliclazide and tolbutamide;
three sulfonylureas commonly used to treat type II, or non-insulin dependent, diabetes.
Figure 4-4 shows how varying the flow rate affected the retention factors measured for
these three analytes. Similar to the results seen for R-warfarin and L-tryptophan, the
relative consistency of the retention factors across all sampled flow rates indicated that
altering the flow rate did not hinder the binding ability of these drugs to the immobilized
protein.
Table 4-2 summarizes the average retention factors measured for each of the
tested drugs over the range of flow rates on both the entrapped HSA and entrapped gHSA
columns. For a more accurate comparison, the retention factors were normalized, by
dividing these values by the measured total protein content (in mg protein per gram
support). All three sulfonylurea drugs showed an increase of approximately 50-60% for
the normalized retention factors on the entrapped gHSA column versus the value
obtained for the entrapped HSA column. This increase in normalized retention factor is
in agreement with previously-reported values for these three sulfonylureas, using the
same sample of gHSA for immobilization.19 All three of these analytes are known to
have two-site binding to HSA, with the majority of the binding attributed to the high
affinity site.11, 12 If the binding affinity to each individual site is known, a global Ka can
be determined by calculating an averaging of the Ka values for each site. This value can
be used for comparison to the Ka values obtained using zonal elution experiments in this
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Table 4-2.

Retention

and

calculated

association

equilibrium

constants

for

acetohexamide, gliclazide and tolbutamide on entrapped HSA and
glycated HSA (gHSA) columns.

HSA

Retention
factor (k)

Normalized retention factor
k/(protein content)a

Ka (M-1)

Acetohexamide

46.5 (± 0.1)

1.26 (± 0.03)

1.6 (± 0.1) x 105

Gliclazide

17.1 (± 0.2)

0.46 (± 0.03)

5.8 (± 0.2) x 104

Tolbutamide

30.8 (± 0.1)

0.84 (± 0.03)

1.0 (± 0.1) x 105

gHSA

Retention
factor (k)

Normalized retention factor
k/(protein content)a

Ka (M-1)

Acetohexamide

62.7 (± 0.1)

1.97 (± 0.06)

2.5 (± 0.3) x 105

Gliclazide

23.4 (± 0.1)

0.74 (± 0.06)

9.3 (± 0.3) x 104

Tolbutamide

47.0 (± 0.2)

1.47 (± 0.06)

1.9 (± 0.1) x 105

The values in parentheses represent a range of ± 1 S.D.
a

These normalized retention factors were calculated by dividing the listed retention

factors by a measured total protein content for the given supports of 37 (± 1) mg HSA per
gram support or 32 (± 2) mg glycated HSA per gram support.
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study. These values are presented in Table 4-3.

The Ka values determined using

entrapped HSA were approximately two times larger than previously reported reference
values. This increase in Ka, although more significant than seen in R-warfarin and Ltryptophan, may also be attributed to the discrepancy in specific activity of the
immobilized protein content used to determine Ka from retention factor.

Conclusions
This chapter used high-performance affinity chromatography zonal elution studies
to examine the changes in binding and overall affinity for various analytes that occur with
the glycation of HSA. Retention factors were calculated using a series of increasing flow
rates. These changes in flow rate had little effect on the binding of all examined drugs to
either immobilized protein. Initial studies examined the binding of two probe compounds
for the two main binding sites on HSA, Sudlow sites I and II. An average retention factor
for the examine flow rates was used to calculated a global Ka value for each analyte on
both the entrapped HSA and entrapped gHSA columns. The normalized retention and
association equilibrium constant for R-warfarin remained constant for both entrapped
HSA and entrapped gHSA. L-tryptophan, however, experienced a nearly three-fold
increase in normalized retention factor, which translated into an increase of Ka from 1.9
(± 0.3) x 104 M-1 to 5.6 (± 0.2) x 104 M-1. This study was extended for the examination of
three sulfonylaurea drugs used for the treatment of type II diabetes. Acetohexamide,
gliclazide and tolbutamide all showed increased binding and association constants with
the glycation of HSA. All Ka values determined on the entrapped HSA column were
slightly higher than previously established values for the same analytes binding to Schiff
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Table 4-3.

Comparison of Ka values calculated using zonal elution experiments to
reference global Ka values on HSA and gHSA with similar levels of
glycation.

HSA

Ka (M-1)

Ka (M-1)a

Reference

Acetohexamide

1.6 (± 0.1) x 105

8.7 (± 0.7) x 104

11

Gliclazide

5.8 (± 0.2) x 104

3.1 (± 0.6) x 104

20

Tolbutamide

1.0 (± 0.1) x 105

5.4 (± 0.2) x 104

11

gHSA

Ka (M-1)

Ka (M-1)a

Reference

Acetohexamide

2.5 (± 0.3) x 105

6.1 (± 0.2) x 104

21

Gliclazide

9.3 (± 0.3) x 104

N/Ab

Tolbutamide

1.9 (± 0.1) x 105

6.5 (± 0.2) x 104

22

The values in parentheses represent a range of ± 1 S.D.
a

These Ka values were determined by calculating the average value of both the low and

high affinity binding sites of each analyte to the protein of interest.
b

Studies are currently being conducted to determine a Ka value for gliclazide on

covalently immobilized gHSA.
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base immobilized HSA.11, 12 This discrepancy could be attributed to the reported
differences in specific activity determine for the two methods.
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CHAPTER 5:
BINDING OF DRUGS TO ENTRAPPED HSA
AND ENTRAPPED AGP SUPPORTS IN HPAC

Introduction
High performance affinity chromatography (HPAC) makes use of the selective
and reversible interactions between an analyte and biologically relevant ligand. This
ligand is immobilized onto a support with sufficient stability to withstand high pressure
conditions. A major advantage of using HPAC for drug-binding studies is the ability for
its supports to be used for multiple experiments. This feature is of great interest when
comparing the binding of a large number of analytes to a specific ligand. Using the same
support for all studies eliminates the variation between immobilized supports.1-4
One desirable feature in the immobilization of a protein for drug-binding studies
is to have the protein in a final form that closely mimics that behavior of the protein’s
native form.

The work in previous chapters examined the ability of entrapped human

serum albumin (HSA) to bind with the site specific probes R-warfarin and L-tryptophan.
This chapter will expand on the use of an entrapped HSA support for the analysis of a
variety of other drugs. This chapter will also introduce the use of an entrapped α1-acid
glycoprotein (AGP) support.
Traditionally, AGP has been immobilized through cross-linking and thiol
coupling. The former has had poor correlation with soluble AGP binding behavior, while
the latter has shown good correlation with soluble AGP for binding with some drugs but
not others.1,

2

Recently, a new immobilization technique has made use of the

115
carbohydrate residues on this glycoprotein. This method immobilizes AGP through
controlled oxidation of these carbohydrate residues, followed by a coupling of this
oxidized protein to hydrazide-activated silica. This immobilization technique has been
shown to give results with better agreement to soluble AGP-binding values than previous
methods.1 This chapter will investigate the use of the entrapment method to immobilize
AGP and compare the measured binding constants for propranolol, a beta-blocker used
for the treatment of hypertension and a drug with well-categorized binding to soluble
AGP with established values.1, 3, 4 The structure of propranolol is given in Figure 5-1.
Both the entrapped HSA and entrapped AGP supports will be used to investigate
the binding of a series of analytes. Several of the analytes are known to bind to these
ligands with a certain affinity, but this study will also investigate the binding of other
analytes where the interactions are unknown. This list of drugs includes amitriptyline
and notriptyline, both antidepressants; chloramphenicol, an antibiotic; chlorpromazine, an
antipsychotic; phenobarbital, an anticonvulsant; quinidine, an antiarrhythmic; and
theophylline, a bronchiodialator. The structures for these seven compounds are shown in
Figure 5-2.
These studies will be preformed using zonal elution, the most popular method
used in chromatographic biointeraction studies.1,4,9

This method was performed by

injecting a small plug of analyte onto the column and measuring the retention time of the
injected analyte. This retention time can be correlated to the association equilibrium
constant, when the void volume and the binding capacity are known. The bulk of this
chapter will be designated to the study the interactions between both AGP and HSA to
the seven compounds listed in the previous paragraph.

116

Figure 5-1.

Structure of propranolol.
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Figure 5-2.

Structures for analytes injected onto both the entrapped HSA and the
entrapped AGP columns.
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Experimental
Reagents.
The p-periodic acid (periodic acid reagent, or H5IO6), glycogen (bovine liver),
HSA (Cohn fraction V, 99% globulin free, 99% fatty acid free), AGP (99%), racemic
propranolol,

amitryptiline,

chloramphenicol,

chlorpromazine,

nortriptyline,

phenobarbital, quinidine, theophylline, monobasic and dibasic potassium phosphate salts,
sodium chloride and sodium acetate were purchased from Sigma-Aldrich (St. Louis,
MO). The Nucleosil Si-300 silica (300 Å pore size, 7 micron particle diameter) was
purchased from Macherey-Nagel (Düren, Germany).

Reagents for the micro

bicinchoninic acid (BCA) protein assay were purchased from Pierce (Rockford, IL).
Other chemicals were of the purest grades available. The Econo-Pac 10 DG disposable
30 x 10 mL desalting columns were purchased from Bio-Rad Laboratories (Hercules,
CA). All solutions were prepared using water from a NANOpure purification system
(Barnstead, Dubuque, IA) and filtered with a 0.20 µm GNWP nylon membrane from
Millipore (Billerica, MA).
Apparatus.
The chromatographic system consisted of a Jasco PU-980i intelligent HPLC
isocratic pump (Tokyo, Japan), a Rheodyne Advantage PF ten-port valve (Cotati, CA),
and a Jasco UV-975 UV/Vis detector. The detection wavelengths were as follows: 205
nm, sodium nitrate; 225 nm, propranolol; 209 nm, amitriptyline; 204 nm,
chloramphenicol; 253 nm, chlorpromazine, 209 nm, nortriptyline; 206 nm, phenobarbital;
234 nm, quinidine; and 209 nm, theophyline. Data were collected using an interface and
software from National Instruments (Austin, TX). The temperature of the columns and
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mobile phases was controlled using a PolyScience circulating VWR circulating water
bath (Buffalo Grove, IL) and a water jacket from Alltech. All columns were packed
using an HPLC column slurry packer from Alltech. The chromatographic data were
analyzed using Peakfit 4.12 (Jandel Scientific Software, San Rafael, CA).
Methods.
Nucleosil Si-300 was converted into a dihydrazide-activated form according to
previously-established procedures.5

Optimized entrapment conditions determined in

Chapter 2 were used to prepare columns containing entrapped HSA, entrapped AGP,
and a control support. The oxidation of glycogen was done in a pH 5.0 buffer containing
20 mM sodium acetate and 15 mM sodium chloride. A 4.0 mL solution was prepared by
dissolving 135 mg of periodic acid and 17 mg of glycogen from bovine liver in the
aforementioned buffer. This solution was covered in aluminum foil – due to the light
sensitivity of periodic acid – and allowed to shake at room temperature for 12-24 h.
After oxidization, the glycogen was purified using an Econo-Pac 10DG disposable
desalting column and pH 5.0, 0.10 M potassium phosphate buffer. This process was done
by first removing the upper cap of the column and decanting the excess storage buffer.
The next step was a buffer exchange via the addition of 10.0 mL of pH 5.0, 0.10 M
potassium phosphate buffer to each column. Next, 3.3 mL of the oxidized glycogen
sample were allowed to pass through the column, causing the elution of the newly
introduced potassium phosphate buffer. A volume of 4.0 mL of potassium phosphate
buffer was then added to the column to elute the oxidized glycogen. The larger glycogen
molecules eluted from the column during this step, while the smaller periodic acid
molecules took much longer to pass through the column matrix. The resulting purified
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oxidized glycogen solution had a concentration of 4.2 mg/mL solution with a final
volume of approximately 4.0 mL. This solution was stored at 4 °C.
Both the HSA and AGP supports were prepared under the same immobilization
conditions. A 50 mg/mL stock solution of each protein was prepared with pH 5.0, 0.10
M potassium phosphate buffer. To create the entrapped support, 80 mg of dihydrazide
activated silica was combined with 160 µL of the protein solution. This mixture was
sonicated under vacuum for 15 min to ensure the proper mixing of the silica and protein.
A 380 µL portion of the purified oxidized glycogen was added, and the mixture was
shaken at room temperature for 12 h. During the final hour of the reaction, 200 µL of a 2
mg/mL oxalic dihydrazide solution in the same buffer was added to the reaction mixture
to cover any remaining aldehyde groups on the silica support. After immobilization, the
support was washed several times with pH 7.4, 67 mM potassium phosphate buffer. A
control support was also prepared through the addition of a 160 µL aliquot of potassium
phosphate buffer in place of the protein solution. Binding of an analyte to this support
was used to monitor non-specific interactions. This control support was used in the
chromatographic studies.
Another portion of Nucleosil Si-300 was converted to diol-bonded silica, and
HSA was immobilized to this support by the Schiff base method according to previouslypublished procedures.5, 6 A control support was also made using this method, without the
addition of HSA.
The protein content of the Schiff base HSA, entrapped HSA and AGP supports
was determined using a micro BCA assay, with soluble HSA or AGP being used to create
a standard curve, and the control support being used as the blank. The entrapped HSA
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support was found to contain 37 (± 1) mg HSA per gram support, the Schiff base HSA
support was found to contain 39 (± 2) mg HSA per gram support, and the AGP support
contained 21 (± 1) mg AGP per gram support.
All supports were downward slurry-packed into separate 1.0 cm  2.1 mm I.D
stainless steel columns at 4000 psi using pH 7.4, 67 mM potassium phosphate buffer as
the packing solution. All columns were stored at 4 °C in the packing solution. All
sample solutions for the chromatographic studies were prepared in pH 7.4, 67 mM
potassium phosphate buffer. Stock sample solutions with a concentration of 100 µM
propanolol and a concentration of 70 µM for all other analytes examined were prepared
in pH 7.4, 67 mM potassium phosphate buffer. The stock solutions were diluted with this
pH 7.4 buffer to give 20 µM working samples of all analytes.
A 20 µL volume of all samples was injected onto the entrapped HSA, entrapped
AGP and control columns in triplicate at 37 °C in the presence of pH 7.4, 67 mM
potassium phosphate buffer. For a majority of the studies, a flow rate of 0.5 mL/min was
used, for those samples with weaker retention, slower flow rates of 0.10 or 0.30 mL/min
were employed to examine the binding of each analyte to the protein of interest. The
void time of each column was determined by making triplicate 20 µL injections of 25 µM
sodium nitrate in the presence of pH 7.4, 67 mM potassium phosphate buffer. The void
time of the system was determined by repeating these injections of sodium nitrate on a
zero-volume union. Peakfit v.4.12 and an exponentially-modified Gaussian curve fit
were used to determine the central moments of all eluting peaks.
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Results and Discussion
Initial binding studies of racemic propranolol to AGP.
Affinity chromatography has been shown to be a useful tool to examine the
overall affinity of drugs to immobilized proteins such as HSA.7 Zonal elution studies can
be used to determine the retention factor (k), which can then be used to calculate the
association equilibrium constant (Ka) of the analyte. Equation 5-1 shows how the
retention factor is related to the Ka for an injected analyte with an immobilized protein,
where mL is the moles of total binding sites in the column and VM is the column void
volume.

k

K a mL
VM

(5-1)

The retention of propranolol on the entrapped AGP column was determined
through zonal elution experiments at flow rates ranging from 0.10-1.00 mL/min. The
retention factor remained relatively constant throughout this range of flow rates, as
indicated in Figure 5-3. This shows that flow rates up to 1.00 mL/min could be used
without causing any significant change in the retention factor. This result is consistent
with data seen for entrapped HSA columns over the same range of flow rates. An
average of these retention values was used to calculate a Ka value for propranolol and
AGP.
The Ka value for propranolol and AGP, calculated from the average measured
retention factor, was 3.1 (± 0.3) x 105 M-1. A variety of association equilibrium constants
have been reported for propranolol and AGP, ranging from 1.0 – 8.4 x 105.1,3,8 The
results obtained in this study fall within this range of values, and are most similar to the
values obtained using equilibrium dialysis under similar buffer and temperature
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Figure 5-3.

Retention factors measured at various flow rates for propranolol on an
entrapped AGP column. The conditions are given in the text. The error
bars represent ± 1 S.D.
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conditions.3 This indicates that the entrapped AGP is accessible for binding by small
molecules like propranolol. The average value for non-specific binding of propranolol to
this column was approximately 28%.
Binding of various analytes to entrapped AGP.
The second phase of this study used entrapped HSA and entrapped AGP columns
to calculate association equilibrium constants for a series of analytes based on their
measured retention factors. Injections were made on a control column to correct for
nonspecific binding to the entrapment support. The interactions between these drugs and
AGP were examined first. Out of the seven drugs studied, both phenobarbital and
theophylline eluted at the void time, showing no apparent binding to the entrapped AGP.
The measured association equilibrium constants for all seven drugs are listed in Table 51, along with published values of Ka for these drugs with soluble AGP.

The data

collected on the entrapped AGP was in good agreement for three of the four drugs with
published data. The measured value for chlorpromazine on the entrapped AGP column
was nearly two-fold higher than the previously reported value. This discrepancy will be
discussed later in this section. No established literature Ka values could be located for
theophylline, chloramphenicol or phenobarbital.
Binding of Various Analytes to Entrapped HSA.
The zonal elution injections were repeated with the same drugs on the entrapped
HSA column, (see Table 5-2). The binding of these drugs to HSA was also analyzed on
a Schiff base HSA column of the same dimensions. This was done to determine if
nonspecific interactions between the injected drugs and the entrapment support had a
significant impact on the resulting association equilibrium constant. These values are
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Table 5-1.

Measured association equilibrium constants (Ka) on the entrapped AGP
support and previously reported values for soluble AGP with various
drugs.

Drug

Ka (M-1)

Ka (M-1)*

Reference

Amitryptyline

7.1 (± 0.3) x 105

> 105

8

Nortriptyline

7.4 (± 0.2) x 105

1.0 – 6.7 x 105

8

Theophylline
Chloramphenicol
Phenobarbitol

a

No Retention

1.9 (± 0.5) x 103
a

8

No Retention

Quinidine

3.0 (± 0.3) x 105

2.0 – 3.0 x 105

8, 9

Chlorpromazine

1.5 (± 0.4) x 106

0.3 -3.9 x 106

8

*For drugs that have a range of association equilibrium constants reported, the average
value of the constants is listed in the table.
The numbers in parentheses represent ± 1 S.D.
a

No retention on the entrapped AGP support.
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Table 5-2.

Measured association equilibrium constants (Ka) on the entrapped HSA
support, the Schiff base immobilized HSA support and previously reported
values for HSA and various drugs.

Drug

Ka (M-1)
Entrapment

Ka (M-1)
Schiff Base

Ka (M-1)*

Ref

Amitryptyline

5.6 (± 0.2) x 104

6.3 (± 0.2) x 104

4.35 x 104

10

Nortriptyline

6.2 (± 0.3) x 104

5.8 (± 0.1) x 104

1.41 x 102

10

Theophylline

4.0 (± 0.6) x 102

9.6 (± 0.1) x 102

Chloramphenicol

1.1 (± 0.5) x 103

1.1 (± 0.1) x 103

2.54 x 104

11

6.4 – 8.9 x 104

12

Phenobarbitol

a

a

N/A

N/A

Quinidine

2.1 (± 0.4) x 104

1.2 (± 0.4) x 104

Chlorpromazine

1.2 (± 0.2) x 105

5.9 (± 0.2) x 104

*For drugs that have a range of association equilibrium constants reported, the average
value of the constants is listed in the table.
The numbers in parentheses represent ± 1 S.D.
a

No retention on the entrapped AGP support.
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also shown in Table 5-2. The results of the binding studies on the Schiff base HSA
column were similar to the results for the entrapped HSA column. Both supports showed
no retention for phenobarbital and minimal retention for theophylline. A significant
discrepancy was noted for the Ka values of chlorpromazine, which were approximately
two-fold higher for the entrapment column. Reference values for the binding affinities of
these drugs on both immobilized and soluble forms of HSA are also listed in Table 5-2.
Values for amitriptyline were consistent for the entrapped HSA, the Schiff base HSA and
the reference value. Values for nortriptyline were in good agreement between the Schiff
base and the entrapment columns, but these values were two-orders of magnitude larger
than the reference value for soluble HSA. While the Schiff base HSA had a Ka value
fairly consistent with the reported literature value for chlorpromazine, the Ka for the same
drug on the entrapped HSA support was 150 – 200% higher. The lack of retention of
phenobarbital and the measured Ka values for theophylline and quinidine were consistent
between immobilization techniques, however no reference values were available for
further comparison in these cases.
The entrapment support and the Schiff base support each had an average of
approximately 30% nonspecific binding for all of the bound drugs, with the exception of
chlorpromazine on the entrapped support. This drug had larger nonspecific interactions
of 60%. All calculated Ka values were adjusted for nonspecific interactions through the
use of a control column. Due to the high value of nonspecific binding obtained for
chlorpromazine, additional injections of all drugs were performed on a column containing
only dihydrazide-activate silica for comparison with the control column to further
investigate the nature of these nonspecific interactions. The retention of the drugs on the
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bare dihydrazide column accounted for an average of 55% of the retention noted for the
control column, indicating that nonspecific binding was taking place not only with the
dihydrazide base of the support, but also with the oxidized glycogen present in the
control column. Further studies are needed to minimize the amount of nonspecific
binding experienced by some drugs on the entrapped support.

Conclusions
This work implemented the use of biologically-relevant ligand entrapment as an
immobilization method for HPAC. Initially, the binding of a well-characterized drug –
propranolol – was investigated through the use of an entrapped AGP column. The results
indicated that this small molecule was able to access and bind to the entrapped AGP with
similar affinity to that seen with soluble AGP. This column, along with an entrapped
HSA column as initially tested through experiments in Chapter 3, were then used to
screen a series of drugs in a pursuit of the determination of association equilibrium
constants for these interactions. The binding of this series of drugs was examined on
both the entrapped AGP and entrapped HSA supports. The use of a Schiff base HSA
support was also used as a means of comparison and to determine if nonspecific
interactions between the analytes and the entrapment support had an appreciable effect on
analyte retention. All measured Ka values were compared to established literature values,
when available. Generally, there was good agreement between the entrapment results
and the established values for these drugs with the soluble form of the examined proteins.
This study indicates that these entrapment columns can be used for the initial
screening of a variety of drugs to determine binding affinity with proteins. Further
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examination of drugs with established binding could then be done using more timeconsuming frontal analysis studies, in order to achieve more detailed binding data. This
method could also be expanded for the use with other affinity ligands, such as
immunoglobulins, to create a series of columns containing additional serum agents to
obtain a more complete profile of the binding of drugs in serum.
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CHAPTER 6:
PREPARATION OF HIGH-CAPACITY SUPPORTS CONTAINING PROTEIN G
IMMOBILIZED TO POROUS SILICA

Introduction
Protein G is a bacterial cell surface protein that is commonly used as a binding
agent for immunoglobulins in affinity chromatography and other analytical methods.1-4
Protein G has strong binding to these targets at pH 5.0-7.5 and yet can be made to release
any retained immunoglobulins at pH 2.5-3.0.2 These properties have made protein G
popular not only as a binding agent for the purification of immunoglobulins but also as a
secondary binding agent that can be used to adsorb antibodies for applications such as
immunoaffinity chromatography or immunoassays.1-4
Over the last decade there have been several examples in which immobilized
protein G has been used in small affinity columns or in affinity capture systems for the
adsorption of immunoglobulins.5-8 The small size of many of these columns and affinity
sorbents requires that a relatively large amount of protein G be present in a small volume
for the effective capture of the desired target.8 However, no previous studies have
determined the maximum amount of protein G that can be placed on common porous
HPAC supports. The goal of this chapter was to estimate the maximum amount of
protein G that could be covalently immobilized to silica with various pore sizes and to
examine the binding of these supports to immunoglobulins.
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Experimental
Reagents.
The Nucleosil Si-50, Si-100, Si-300, Si-500, Si-1000 or Si-4000 (all 7 μm
diameter with nominal pore sizes of 50 Å, 100 Å, 300 Å, 500 Å, 1000 Å, 4000 Å,
respectively) were purchase from Alltech (Deerfield, IL). The protein G (recombinant,
albumin binding domains removed), rabbit immunoglobulin G (IgG), monobasic and
dibasic potassium phosphate salts, sodium cyanoborohydride, and sodium borohydride
was from Sigma-Aldrich (St. Louis, MO) or Pierce (Rockford, IL). Reagents for the
bicinchoninic acid (BCA) protein assay were also from Pierce.

All solutions were

prepared using water from a NANOpure purification system (Barnstead, Dubuque, IA)
and filtered with a 0.20 µm GNWP nylon membrane from Millipore (Billerica, MA).
Apparatus.
Samples for a micro BCA protein assay were analyzed using a Shimadzu UV
160U absorbance spectrophotometer (Kyoto, Japan). The protein and supports were
mixed using an Aliquot 4651 Mixer from Ames (Elkhart, IN). Columns were packed
using a CM3200 pump from Thermoseparations (Riviera Beach, FL) with a modified
Valco N60 six-port valve (Houston, TX, USA).

Chromatographic studies were

conducted using a Thermoseparations CM3200 pump, two Rheodyne six-port injection
valves (Cotati, CA), two Jasco PU980 pumps (Tokyo, Japan) and a Thermoseparations
SM3100 variable wavelength detector.
Methods.
Protein G was immobilized onto silica for use in sandwich microcolumns.
Supports with six different pore sizes were prepared to determine total immobilized
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protein G content as a function of porosity. All of the supports used in this study were
HPLC-grade porous silica with an average particle size of 7 m and nominal pore sizes
of 50 Å, 100 Å, 300 Å, 500 Å, 1000 Å or 4000 Å. According to the manufacturer, these
supports had surface areas of 420, 350, 100, 35, 25 and 10 m2 per gram, respectively. All
silica samples were converted into a diol-bonded form, which was then used to
immobilize protein G by the Schiff base method, according to methods adapted from the
literature for use with other proteins.9, 10
Each reaction mixture contained 100 mg of silica and approximately 3 mg of protein
G in pH 6.0, 0.10 M potassium phosphate buffer. The samples were degassed under
vacuum for 5 min and then allowed to shake for seven days at 4 °C in the presence of
100 mg per ml sodium cyanoborohydride. The immobilization reaction took place at
pH 6.0 because this promotes immobilization at the N-terminus of the protein rather
than at its lysine residues.11 Immobilization at the lysine residues decreases the
activity of the protein because of incorrect orientation for binding of the analyte.
At the end of the immobilization period, the supports were washed four times
with water, once with pH 8.0, 0.10 M potassium phosphate buffer, and allowed to shake
for 90 min with 2 mg per ml sodium borohydride to remove excess aldehyde groups on
the silica. The supports were again washed with water and pH 7.4, 0.10 M potassium
phosphate buffer, and stored at 4 °C in the pH 7.4 buffer. A portion of each support was
set aside for an analysis of protein content using a micro BCA assay.
Each slurry was diluted to the desired concentration and used to pack a sandwich
microcolumn.4 Six 1.0 cm x 2.05 mm I.D. microcolumns were packed, each containing a
support of a different pore size. A thin layer of inert diol-bonded silica was first packed
into the column, followed by a series of 64 injections of protein G silica, each with a
volume of 90 μL. The remainder of the column was filled with diol-bonded silica until
the pressure was over 3000 psi, indicating that the column was full. Next, the flow rate
was decreased until the backpressure on the column reached 3000 psi (the desired
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packing pressure) and the column was then allowed to equilibrate for 20 min or until the
pressure stabilized. Columns of the same length and inner diameter were packed with
diol-bonded silica to find the column void time and to examine non-specific binding of
analytes to such columns.
A micro BCA assay was used to determine the protein content of each
microcolumn. The set aside portions of the immobilized supports were washed with
water and dried under vacuum without heat or organic solvents. The samples were
examined in triplicate, with bovine serum albumin (BSA) as the standard. An assay was
run to compare the responses of protein G and BSA in the BCA assay. There were no
notable differences between the responses of the two proteins, indicating that BSA could
serve as a suitable substitute for preparation of the standard curve. The concentration of
protein per gram of silica was calculated for each sample.
Frontal analysis studies were performed to examine the binding of IgG to the
immobilized protein G supports in all six microcolumns.

Solutions of varying

concentrations of IgG were made in pH 7.4, 0.10 M potassium phosphate buffer. The
IgG solution was continuously applied to the protein G column until all binding sites
were saturated, producing a breakthrough curve. After each run, the columns were
washed for approximately 10 min at flow rates of 1 to 2 ml per min with pH 2.5, 0.10 M
potassium phosphate buffer, to elute the IgG remaining on the column. Finally, the
column was regenerated through the application of pH 7.4, 0.10 M potassium phosphate
buffer for 10 min at 1.00 mL per min. The flow rate was then decreased slowly to 0.10
mL per min and the next run began. All runs were performed in triplicate on each
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immobilized protein G column and corresponding inert diol-bonded silica column to
serve as the control.
Breakthrough times for column and control column were determined by using the
equal area method.

The amount of analyte needed to saturate these columns was

determined by integration of the resulting breakthrough curves, after correcting for the
void time of the system and non-specific binding to the support, as measured on the
control column. The nonspecific binding for these supports accounted for less than 5%
of total binding.
These studies were conducted to determine not only the amount of bound IgG, but
also the specific activity of each support. The moles of IgG bound to the column were
found by multiplying the time required to reach the breakthrough point by the flow rate
and IgG solution concentration. The specific activity of each column was determined by
dividing the amount of IgG bound to the column by the total protein G content, as
determined by a micro BCA assay.

Results and Discussion
Effect of Porosity on the Amount of Immobilized Protein G.
Recombinant protein G with the albumin binding domain removed was covalently
immobilized onto supports with six different porosities, using the Schiff base
method.2 This method has been shown in previous work to give higher activities for
protein G and protein A (i.e., a related bacterial cell wall protein) than other aminebased coupling methods.2,3,9 The concentration of protein G used for immobilization
was two-fold larger than the maximum amount that was later found to be
immobilized to any of the materials that were examined in this study. A micro BCA
assay was used to determine the protein content of all six protein G supports.12
Figure 1A shows the maximum amount of protein G that was immobilized using
the Schiff base method onto silica with various pore sizes. Each sample was measured in
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triplicate using a mirco BCA assay. The highest protein content was obtained for the 100
Å support, which contained 1.56 (± 0.04) μmol protein G per gram support or 39 (± 1)
mg protein G per gram support (note: the numbers in parentheses represent ± 1 standard
deviation of the mean). The second highest amount was obtained for the 50 Å support,
which gave 33 (± 1) mg protein G per gram support. A decrease in the amount of
immobilized protein G per gram of support was seen as the pore size increased to 300
through 4000 Å, with roughly 21-24 mg protein G per gram support being obtained for
the 300-1000 Å pore size supports and 9.3 mg protein G per gram support being
measured for 4000 Å pore size supprt.
It has previously been suggested in work with the immobilization of other
proteins, and in theoretical calculations of effective diffusivity, that the optimum pore
size for protein immobilization is roughly 3-5 times the diameter of the protein.13,
Based on a previous crystal structure and hydrodynamic studies,15,

16

14

the estimated

diameter of recombinant protein G with the albumin binding removed was less than 3035 Å. This size range agreed with the data shown in Figure 1A, which confirmed that a
maximum protein content was obtained when using a support with pores that were

141

Figure 1.

Amount of protein G that was immobilized by the Schiff base method to
silica with various pore sizes. The results are shown in terms of (A) the
moles or mass of protein G that was immobilized per gram of support
and (B) the moles or mass that was immobilized per unit surface area of
the support. The error bars represent a range of ± 1 S.D. of the mean (n
= 3).
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roughly three times the diameter or protein G (i.e., as noted when using 100 Å pore size
silica).
The amount of immobilized protein G was also examined in terms of the quantity
that was coupled per unit area for each type of silica. These results, shown in Figure 1B,
indicate that there was an increase in amount of immobilized protein G per unit area as
the pore size of the support was increased. This effect has been observed in previous
studies for other proteins (e.g., IgG and Fab fragments)13 and is a result of the protein
being able to access more surface area on the support as the pores increase in size. The
use of a support with a pore size of 300 Å or smaller resulted in a large fraction of the
total surface area being inaccessible to protein G, thus resulting in a relatively low
surface coverage. Silica with a pore size of 500 Å or larger gave a dramatic increase in
surface coverage, with a maximum value of 0.037 (± 0.003) μmol per m2 or 0.93 (± 0.08)
mg per m2 being measured for 4000 Å pore size silica. This trend fits with previous
observations that have been made with other proteins on porous silica.13
Rabbit IgG Frontal Analysis Studies.
The binding capacity and activity for each protein G support were examined by
placing these materials into affinity columns and conducting frontal analysis. Rabbit IgG
was used as the model analyte for this work. The results are summarized in Figure 2. In
Figure 2A, the 50 Å and 100 Å pore size supports gave the largest overall binding
capacities for rabbit IgG, with values in the range of 71 – 77 mg protein per g support.
As the pore size of the support was increased to larger values, there was a decrease in
binding capacity that followed the general trend noted for the total amount of
immobilized protein G in Figure 1A. The maximum binding capacities obtained in this
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Figure 2.

Amount of rabbit IgG that was adsorbed to protein G supports prepared
by using silica with various pore sizes. The protein G supports that were
used in this figure were the same supports examined in Figure 1. The
specific activities were calculated by assuming a maximum of one IgG
could bind to each protein G molecule. The error bars represent a range
of ± 1 S.D. of the mean (n = 3).
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were approximately 1.6 – to 1.7 – fold higher than values listed for commercial supports
that contain protein G immobilized to comparable materials.
The apparent activity of the immobilized protein G in each type of column was
found by dividing the measured binding capacity by the total amount of immobilized
protein G. These results are given in Figure 2B. In this case, all of the supports had
similar apparent activities in the range of 30-47%. These values indicated that about one
out of every three protein G molecules could bind to rabbit IgG when the support was
saturated with this target. Some of this protein G may have lost its activity during
immobilization, a possibility that has been seen in work with protine A.9 Steric hindrance
between neighboring protein G molecules in their binding to IgG would also be expected
to account for part of the drop in apparent activity below 100%. The similarity of the
apparent activities in Figure 2A indicates that steric hindrance arising from pore size
effects was not an issue for the adsorption of IgG to protein G that had been immobilized
to the 50 to 4000 Å porous silica.
Previous work has examined the amount of rabbit IgG that can be covalently
immobilized to the same types of supports that were used in this present study13. Both
general

amine-based

coupling

methods

(e.g.,

the

Schiff

base

and

1,1’-

carbonyldiimidazole techniques) and a site-specific immobilization technique (e.g., the
coupling of IgG through oxidized carbohydrate chains in its Fc region to a dihydrazideactivated support) were studied in the previous report. The results for these various
methods were fairly comparable, with contents for rabbit IgG of 212 (± 20) mg per pgram
support being obtained for 100 Å pore size silica and 255 (± 12) mg per gram support
being reported for 300 Å pore size silica when using site-selective coupling by the
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dihydrazide method.13 A comparison of these values with those in Figure 2A indicates
that the covalent coupling of immunoglobulins/antibodies to these supports can allow for
about a three-fold higher maximum coverage of these agents than when using secondary
adsorption of the same agents to immobilized protein G.

Conclusions
In summary, this report investigated the immobilization of protein G to silica
supports with regards to the maximum protein content that could be obtained for these
materials. A maximum content of 39 mg protein G per gram support was obtained when
using 100 Å pore size silica, with a slightly lower level being obtained for 50 Å silica and
even lower levels for 300 Å to 4000 Å silica. These data agreed with previous
observations that maximum content for an immobilized protein is generally obtained
when using a pore size that is three to five times the diameter of the protein. The surface
coverage of protein G was found to increase with pore size, with a maximum level of
0.037 mol/m2 being obtained for 4000 Å silica.
When the binding of these supports for immunoglobulins was determined using
frontal analysis, all gave apparent activities in the range of 30-47% for rabbit IgG, with
the highest binding capacities (i.e., 71 – 77 mg IgG/g silica) being obtained for the 50 and
100 Å silica supports. Although these values are lower than those that can be obtained
for the covalent immobilization of antibodies, they should still be appropriate for the use
of protein G in affinity microcolumns or miniaturized analytical systems.5-8 In addition,
using

protein

G

as

a

secondary

binding

agent

can

allow

adsorbed

immunoglobulins/antibodies to be released at a mildly acidic pH for column regeneration,
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and this binding agent can allow a variety of immunoglobulins/antibodies to be adsorbed
to the same support.2-8 The ability of protein G to attach to the Fc region of
immunoglobulins is another attractive feature that can aid in obtaining site-selective
attachment and high activity for adsorbed antibodies. These properties should continue to
make protein G supports, like those developed in this report, valuable tools in
immunoaffinity separations, immunoassays and related bioanalytical applications.
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CHAPTER 7:
SUMMARY AND FUTURE WORK

SUMMARY OF WORK
Optimization of the Entrapment Method.
The proper use of high performance affinity chromatography (HPAC) in the study
of biologically-related systems requires that careful attention be paid to the nature in
which the affinity ligand is incorporated into the stationary phase. Ideally, the behavior
of the immobilized ligand should mimic the behavior of the ligand in its natural
environment.

Retaining the soluble form of the ligand, by avoiding covalent

immobilization completely, is one effective way to retain the activity of the ligand.
Previously, noncovalent immobilization techniques that do not modify the ligand of
interest have included physical entrapment onto low performance supports.
This dissertation has introduced an alternative method of entrapment onto
supports that can withstand the high pressures and flow rates associated with HPAC.
The entrapment method is based on the physical containment of a ligand in a
polysaccharide-capped dihydrazide support.

In Chapter 2, initial chromatographic

studies were performed in order to determine the activity of proteins in the entrapped
support. This was done by preparing HPAC columns that contained an entrapped HSA
support, and conducting frontal analysis experiments with probe compounds for the
major binding sites on HSA.

It was determined that the entrapped HSA retained

essentially 100% of its binding activity, making this immobilization technique a viable
alternative to traditional covalent immobilization methods.
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A variety of experiments were then conducted to optimize the protein content of
these supports. These experiments included varying the pore size of the support, the
amount of glycogen in the reaction mixture, the amount of ligand in the reaction mixture,
the time allowed for the entrapment process to occur, and the level of periodic acid used
in the oxidation of glycogen. The resulting protein content was determined for each
study, and optimum conditions were selected.

The entrapment method was also

expanded for use with other immobilized ligands. A range of different molecular weight
ligands were tested in the method, and it was determined that a range of 5.8-150 kDa
moleculare weights could be successfully entrapped, with smaller amounts of ligand
entrapment occurring for molecular weights up to 450 kDa. It was also determined that
high capacity supports could be produced, with protein contents up to four times higher
than seen with traditional immobilization techniques.

Implementation of Entrapment Supports for Use in HPAC Binding Studies.
It was found in Chapter 2 that as the level of periodic acid used in the initial
oxidation of glycogen increased, the binding capacity of the entrapped support also
increased. The work in Chapter 3 involved the use of several columns, each prepared
with a different amount of periodic acid in the reaction mixture. Zonal elution studies
were performed at multiple flow rates on all supports to determine how the retention of
the aforementioned probe compounds was affected. The measured retention factors for
each individual column remained consistent over flow rates ranging from 0.10 – 1.00
mL/min, indicating that higher flow rates could be used with these 1.0 cm columns
without impacting the retention of these analytes. When the columns were compared
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with each other, there was not only a notable decrease in retention factor for higher
oxidation levels but also a notable decrease in column efficiency. These results indicated
that higher levels of oxidation inhibit the ability of the analyte to bind to the entrapped
support.

Several drugs were injected onto both sets of columns, and the resulting

correlation chart showed a 70% higher normalized retention factor for analytes injected
on the entrapped HSA column versus the Schiff base column, reinforcing previous data
for indicating the higher activity of the entrapped ligand.
Chapter 4 examined the binding of three sulfonylurea drugs to both entrapped
HSA and entrapped glycated HSA (gHSA). The binding ability of the entrapped gHSA
column was initially tested using probe compounds with known binding to HSA. These
results indicated that the gHSA was accessible for binding. The zonal elution data
obtained for the injections of sulfonylurea drugs were in agreement with previously
reported values for the binding of these drugs to gHSA. An increase in normalized
retention factor was seen in these experiments for the entrapped supports when compared
to Schiff base supports.
The studies in Chapter 5 focused on the use of the entrapment columns as a
screening tool to examine a wide range of analyte binding affinities. These experiments
were conducted using both entrapped HSA and entrapped AGP supports. The entrapped
AGP support was initially tested for viability through the injection of a compound with
known retention to this glycoprotein. Resulting data showed that the entrapped AGP was
accessible to small analytes for binding, with measured association equilibrium constants
that were in agreement with previously-established literature values. A series of zonal
elution injections for seven drugs was performed on the entrapped HSA, the entrapped
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AGP, and the prepared control column. Injections were made on the control column to
account for nonspecific binding between the analyte and the support. Measured Ka
values were compared with established literature values when available.

Preparation of High Capacity Protein G Supports.
The final study in this dissertation focused on the covalent immobilization of
protein G using the Schiff base method – a method that was often used for comparison in
the entrapment studies.

These supports were optimized to achieve maximum

immobilized protein content through the variation of pore size. The ability of this
immobilized protein G to selectively attach to the Fc region of immunoglobulins was
examined. This type of adsorption creates a stationary phase containing highly active
antibodies, which is useful for the immunoaffinity separations.

FUTURE WORK
Entrapment.
The optimization of the entrapment method has created many options for further
implementation of this method. The high protein content supports, prepared using 100 Å
silica and high levels of ligand in the reaction mixture, will be used to make HPAC
columns for future binding studies. At the optimum periodic acid ratio determined in the
preliminary studies, the amount of glycogen oxidation should allow for complete access
of the analyte to the immobilized ligand. A support with such high protein content would
make it possible to study analytes with relatively low affinities and to avoid experimental
problems such as sample overloading. The work done in this dissertation showed that
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analyte retention on these supports was not affected at flow rates up to 1.00 mL/min.
Using this moderately high flow rate, a high protein content support would make it
possible to create an efficient screening method that could obtain binding affinities for
analytes that have not yet been studied by HPAC.
The entrapment method has been shown to be viable with a wide range of ligands
at various molecule weights. The ability to entrap a large variety of ligands will allow
production of new affinity supports. For example, work has been done to prepare an
entrapped streptavidin support with a relatively high measured protein content of 56 (± 1)
mg streptavidin per gram support. The activity of this support still needs to be tested. If
sufficient activity is present, this support could be combined with biotinylated
compounds of interest, which could be bound to the streptavidin stationary phase and
used for affinity binding studies. This would make it possible to extend the entrapment
method for the use of ligands with small molecular weights outside the optimized range.
The different genetic variants of AGP could also be entrapped, to obtain binding
information specific to each variant.
The work in Chapter 4 with commercially gHSA will next be extended for work
with gHSA from human serum samples obtained from diabetic patients. The nature of
the entrapment method makes it viable for automation. Figure 7-1 shows a proposed
scheme to carry out the entrapment immobilization in an online fashion extending from
serum injection to finished HPAC column. The first step would be to purify the HSA (or
the protein of interest) from human serum using the binding specificity between albumin
and its immobilized antibodies. An anti-albumin antibody agarose resin will be prepared
with a size large enough to accommodate the quantity of HSA needed for later
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Figure 7-1. Schematic for online HSA entrapment from serum.
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entrapment. Current resins available from Vivapure® have a binding capacity of 2
mg/mL and 5 mL of a 50% resin slurry could purify the HSA in 20 µL of serum or up to
800vµg of HSA. Larger columns could be produced to process larger volumes of serum.
This purification step will be done by first flowing binding buffer through the column, a
Tris-based buffer of low salt concentration between pH 7.0-7.5. Next, a known volume
of human serum, with a size compatible with the amount of resin, would be injected onto
the column.

All non-bound proteins will be eluted from the column during the

application of binding buffer and collected in an excess container. This washing step will
ensure that only purified HSA is present on the resin. The next step would be to elute the
HSA from the resin. This will be done by the application of an elution buffer, 0.10 M
glycine/HCl at pH 2.8. The bound HSA would be eluted from the resin into a size
exclusion column where the pH 2.8 buffer will be exchanged for 0.10 M potassium
phosphate buffer at pH 5.0 for compatibility with the entrapment method. The HSA will
now be cycled through an HPAC column containing dihydrazide-activated silica. Next,
oxidized glycogen will be added to the HSA mixture and cycled through the column.
This step will create the entrapped support. The final step will be to make a small
injection of oxalic dihydrazide to cover any remaining aldehyde groups on the support to
minimized non-specific binding. The column will then be washed with pH 7.4 potassium
phosphate buffer prior to use in HPAC.
Studies conducted during the optimization of the entrapment rate employed initial
silica samples of only 3 mg for the successful entrapment of HSA.

These results

indicated that small columns with relatively high binding capacities could be made using
these human serum samples. Current studies are being done to test the ability for
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entrapment to occur in pH 2.8 buffer. This would eliminate the buffer exchange step in
the proposed online procedure allowing for the entrapment HPAC columns to be
prepared from serum to support with minimal exposure and human interference.

